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The epidemiology of measles in many countries, including South Africa, has changed 
from being a disease that primarily occurred in pre-school children up till 1991 to that 
which now occurs frequently in schoolchildren and older individuals. In the presence of 
high measles vaccination coverage, the role of waning immunity has been suggested for 
the loss of protection against measles in these schoolchildren and older individuals. Thus 
the administration of more than one dose of measles vaccine is necessary for the 
sustained control of measles. This gives the opportunity to study the immune responses 
to measles virus when antibodies are already present. Immune responses could also be 
dependent on the presentation of the antigen (mucosa) versus subcutaneous). Information 
is lacking on vaccine strain effects, particularly when given as an aerosol. Although 
historical data suggest that the aerosol route might be more immunogenic for booster 
doses than traditional subcutaneous injections, there have been no randomised 
comparative trials. In mass measles campaigns, the aerosol route of vaccination would be 
easier and quick to administer to a large number of children. The aerosol route is 
attractive over the subcutaneous route as it is painless and avoids the risks of 
transmission of blood borne infections. 
Objectives 
1. To randomise schoolchildren, most of whom that have been previously vaccinated
against measles, into 4 groups to receive two different measles vaccine strains
(Schwarz or Edmonston-Zagreb (EZ)) given by two different routes of administration
(subcutaneous injection or aerosol).
2 
2. To compare the serological responses in the different strain-route groups at 1 month, I
year and 2 years after vaccination in all children with low or absent antibody levels and
in a sample of children with high antibody levels at baseline.
3. To investigate the effect of previous and concurrent upper respiratory tract infections
on serological responses.
4. To investigate the frequency of adverse events after vaccination in the different groups
and in the aerosol vaccinators.
Methods 
We assigned 4987 primary schoolchildren (5-14 year old) by block randomisation of 
classrooms to receive standard titre doses of either Schwarz or Edmonston-Zagreb 
measles vaccines subcutaneously or by aerosol. Blood samples for antibody assay were 
collected on the day of vaccination from all children present. All children who were 
seronegative, as well as a 9% random sample of seropositives, were subsequently 
followed up at 1 month, I year and 2 years post-vaccination. The fieldwork was 
conducted between July 1996 and September 1998. Antibody titres were determined 
using the haemagglutination inhibition assay, with a cut-off of I :4 which corresponded 
approximately to 300 milli-intemational units per ml (mIU/ml). The main endpoints 
(antibody titres at l month, !year and 2 years after vaccination) were compared between 
groups. 
Results 
82.4% of children had histories of previous vaccination and only 5% of the children 
mounted an IgM response, suggesting that nearly all the children had been previously 
exposed to measles antigens. Of those that were initially seronegative at baseline or were 
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part of the random sample of seropositives, 992 children had antibody titre data available 
for each of the 3 sampling time-points that were used for initial analyses (pre­
vaccination, 1 month and 1 year). The initial results based on these children showed that 
Edmonston-Zagreb vaccine by aerosol was significantly better at boosting titres at 1 
month and 1 year than any of the other vaccine groups. Seroconversions (proportion with 
at least four-fold titre increases from baseline) in the Edmonston-Zagreb aerosol group at 
1 month and l year were 85% and 60%, compared to Edmonston-Zagreb vaccine given 
subcutaneously (79% and 34%) and Schwarz vaccine given subcutaneously (63% and 
25%). The Schwarz aerosol group performed poorly, and its reconstituted vaccine was 
found to lose potency quickly in the nebuliser. 
Measles antibody persistence assessed up to 2 years after revaccination for 851 
of the 992 children showed that at 2 years, seroconversions from baseline continued to be 
significantly more frequent for Edmonston-Zagreb vaccine by aerosol (55%) than for 
Edmonston-Zagreb vaccine subcutaneously (23%) and Schwarz vaccine subcutaneously 
(21 %). The Edmonston-Zagreb aerosol group had the lowest proportion of children who 
became seronegative at 2 years (6%) compared to Edmonston-Zagreb vaccine 
subcutaneously (12%) and Schwarz vaccine subcutaneously (19%). For all groups, 
geometric mean titres declined substantially from l month to I year but the rate of 
decline flattened out in the second year post-vaccination. The geometric mean titres 
remained highest for Edmonston-Zagreb vaccine by aerosol (1: 13), with Edmonston­
Zagreb vaccine subcutaneously and Schwarz vaccine subcutaneously both being l :7. 
Seroconversion was significantly reduced in children who reported illness in the 
month before vaccination compared to those without any illnesses. There was a 
borderline reduction in effect of Edmonston Zagreb vaccine by aerosol in presence of 
cough but not with rhinitis (p=O. l ). However, the average antibody titre increases in 
those with these symptoms in the aerosol group still exceeded the overall responses in 
the subcutaneous groups 
Adverse events m the 2 weeks post-vaccination were lower in the aerosol 
groups compared to the subcutaneous groups. Fewer children in the aerosol groups were 
absent, took medications or consulted a doctor compared to the subcutaneous groups. 
Except for a higher frequency of fever in the Edmonston-Zagreb subcutaneous group in 
year 1, there were no significant differences in illnesses between groups in the first and 
second year following vaccination. There was no significant boosting in antibody titres 
in the vaccinators nor were there any overt clinical symptoms experienced by them. 
Thus, the aerosol vaccination was safe to both the vaccinees and vaccinators. 
Conclusions 
The trial afforded an opportunity to study important immunological responses in 
measles. The immunological responses to different vaccine strains administered by 
different routes have been clearly demonstrated. EZ vaccine administered by the aerosol 
route produced significantly higher and more persistent antibody responses after re­
vaccination than any of the other strain/route combinations tested. We believe the aerosol 
route using presently available devices is safe (to both vaccinees and vaccinators), 
painless, effective and readily adaptable to mass campaigns, and that this approach could 
significantly abet global measles elimination/eradication efforts. 
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CHAPTER 1 
Purpose and objectives 
1.1 Purpose 
The purpose of this study was to get a greater understanding of the antibody responses to 
different measles vaccine strains when administered by different routes. Such studies are 
required to facilitate programmes aimed at further global control and elimination of 
measles. This trial contributed towards achieving this purpose by comparing the serological 
responses at 1 month, 1 year and 2 years after vaccination to Schwarz or Edmonston Zagreb 
measles vaccines administered by the subcutaneous or aerosol route in schoolchildren. 
1.2 Objectives 
1.2.1 To randomise schoolchildren, most of whom have been previously vaccinated for 
measles, to receive one of four combinations of two different measles vaccine 
strains (Schwarz or Edmonston-Zagreb) given by two different routes of 
administration (subcutaneous injection or aerosol) 
1.2.2 To measure the baseline measles antibody levels in these children and identify 
those with high, low or absent measles antibody levels. 
1.2.3 To compare the serological responses in the different strain-route groups at 1 
month, 1 year and 2 years after vaccination in all children with low or absent 
antibody levels and in a sample of children with high antibody levels. 
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1.2.4 To investigate the effect of previous and concurrent upper respiratory tract 
infections on serological responses 
1.2.5 To investigate the frequency of adverse events after vaccination in the different 





Measles is a highly contagious acute viral disease characterised by fever, cough, 
coryza, conjunctivitis, and a pathognomonic enanthem (Koplik's spots), followed by a 
generalised maculopapular eruption (Norrby and Oxman, 1990). The virus is transmitted 
primarily from person to person by large respiratory droplets or aerosols when an 
individual in the catarrhal stage of the disease talks, coughs or sneezes. Once accepted as 
an inevitable part of childhood, isolation of the measles virus in 1954 by Enders and 
Peebles and subsequent development of vaccines against this virus has changed the 
epidemiological pattern of this disease wherever it has been extensively used (Black, 
1984). Immunisation against measles has proved to be the safest and most effective way of 
reducing the morbidity and mortality from this disease. Ilowever, measles remains one of 
the major causes of childhood mortality in developing countries. In Africa, it was 
estimated in 1997 that there were about 11 million cases of and about 550 000 deaths from 
measles. 
2.2 Measles virus 
Measles virus 1s a member of the genus Morbillivirus in the family 
Paramyxoviridae (Kingsbury et al 1988). Measles viruses are spherical, enveloped single 
stranded RNA viruses. There are six identified structural proteins; three proteins 
complexed with viral RNA, and three proteins in the virus envelope (Norrby and Oxman, 
1990). The envelope components comprise the M protein in the inner surface and the H 
and F proteins on the outer surface. The H protein attaches the virus to cell surfaces. The 
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F protein fuses virus and cell membranes, allowing viral penetration of the cell and cell 
destruction. 
2.3 Mode of infection and clinical aspects of the disease 
Measles is a ubiquitous, highly infectious disease affecting nearly every person in 
a given population by adolescence in the absence of immunisation programmes (Black 
1984 ). Measles is transmitted primarily from person-to-person by large respiratory 
droplets or by the airborne route as an aerosol. Measles is most infectious during the 
prodrome. First there is localised infection of the respiratory epithelium of the 
nasopharynx and possibly the conjunctivae, with spread to regional lymphatics. Primary 
viremia occurs 2 to 3 days following exposure, and an intense secondary viremia occurs 
3 to 4 days later. The secondary viremia leads to infection of and further replication in 
the skin, conjunctivae, respiratory tract and other distant organs. The amount of virus in 
blood and infected tissues peaks 11 to 14 days after exposure and then falls off rapidly 
over the next 2 to 3 days (Cutts 1993). 
These events correspond with an incubation period between exposure and the 
onset of symptoms of IO to 12 days. The prodomal period then begins, with fever, 
malaise, conjunctivitis, coryza, and tracheobronchitis. The appearance of enanthema and 
erythema mark the end of the prodrome. Koplik spots appear on the buccal musoca 1 to 2 
days before rash onset and may be noted for an additional I to 2 days after rash onset. 
The rash is an erythematous maculopapular eruption that usually appears 14 days after 
exposure and spreads from the head to the extremities over a 3 to 4 days period. Over 
the next 3 to 4 days, the rash fades; in severe cases desquamation may occur. Other 
constitutional signs and symptoms, such as anorexia, diarrhoea and generalised 
lymphadenopathy may also be present (Preblud and Katz 1988). 
2.4 The immunological response to natural infection 
The body's mucosa! surfaces, tissues and blood all need to be protected against 
infections and antibodies of different isotypes are adapted to function in different 
compartments, namely systemic and mucosa!. 
Systemic compartment: 
In primary acute infection, there is a B cell (Norrby and Gollman 1972) and T 
cell (Graziano et al 1975) response to most of the six measles virus proteins. Both IgM 
and IgG antibodies are initially produced, however IgM antibodies peak at 7-10 days 
after rash onset and fall rapidly, rarely being detectable more than 4 weeks after rash 
onset. Serum IgA is also produced but is usually transient (Pederson et al 1986). IgG 
antibodies become detectable in the serum within the first days of rash onset, peak within 
about four weeks and subsequently decline somewhat, but persist for life (Stokes et al
1961 ). The IgG antibodies to the H protein appear to be most important in determining 
immunity (Black 1989, Norrby and Oxman 1990). 
Immunity after natural infection is usually lifelong (Panum 1940, Black and 
Rosen 1962). The antibody induced by immunization with attenuated measles virus 
reaches lower peak titres than those induced by wild virus (Krugman et al 1965, 
Hilleman et al 1968, Krugman 1983). Antibody persists longer when there is boosting 
from exposure to circulating wild virus (Krugman 1977, Krugman 1983, Zhang and Su 
I 983 ). When measles antibody titres fall to low levels, re-exposure to measles virus 
(wild or vaccine virus) stimulates memory cells, which are B cell clones primed to 
produce specific IgG which remain dormant after the initial infection. An anamnestic 
(secondary) immune response occurs, in which titres of IgG rise rapidly and peak 
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approximately 12 days after reinfection (Krugman et al 1965, Schleuderberg 1965). If 
antibody titres are high prior to exposure, reinfection is prevented and a boost in titre is 
rarely seen (Krugman 1977, 1983, Zhang and Su 1983, Zhuji measles vaccine study 
group 1987). Since viruses replicate inside cells where they cannot be detected by 
antibodies, destruction of these viruses infected cells is by T lymphocytes (Janeway et al
1999). Cell-mediated immunity plays an important role in recovery from, and possibly 
prevention of measles, and it has been postulated that sufficient stimulation of cell­
mediated immunity may be a prerequisite for the development of lifelong protection 
(Gallagher et al 1981 ). However, tests for cell-mediated immunity are less readily 
available than those for humoral immunity and the role of cell-mediated immunity in 
providing long-term immunity after immunization has not been as clearly defined. An 
emerging theme is that measles virus immunity is conferred by appropriately polarised 
anti-viral CD4+ and CD8+ cell populations (van Els and Nanan 2002). Recent 
technological advances have permitted the analysis of the composition and dynamics of 
these CD4+ and CD8+ T cell responses at single cell level (Nanan et al 2000). They 
have shown that measles virus-specific CD4+ and CD8+ T cells are readily detectable 
long after acute infection and are thus contributing to long-term immunity. Others have 
also shown the role of CD4+ and CD8+ T cells in memory, control and elimination of 
measles infection (van Binnendijk et al 1990, Nanan et al 1995, Jaye et al 1998). 
Mucosa) compartment: 
Most vaccines are given by injection. However, in addition to the practical 
drawbacks, the immunological drawback is that the injection is not the usual route of 
entry of the majority of pathogens against which the vaccination is directed. Many 
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respiratory and enteric microorganisms infect mucosal surfaces or enter the body through 
mucosal surfaces (Janeway et al 1999). Examples of these include respiratory 
microorganisms such as measles, pertussis, rhinoviruses and influenza viruses, and 
enteric microorganisms such as polio, rotaviruses and cholera. Exposing mucosa) 
membranes to vaccines is a strategy that can produce an immune response in a less 
stressful and better targeted manner. The oral polio vaccine, in use since 1950s, is an 
early example of the effectiveness of this strategy. This shows that the route of entry of a 
disease-causing organism is also an effective vaccine route as well. 
Mucosa! membranes are located throughout the body but are the most accessible 
to microorganisms in the lungs, nose, mouth, throat, gastrointestinal tract, rectum and 
vagina. The mucosal-associated lymphoid tissue (MALT) comprises all lymphoid cells 
in epithelia and in the lamina propria lying below the body's mucosa! surfaces. The main 
sites of MALT are the gut-associated lymphoid tissues (GALT) and bronchial-associated 
lymphoid tissues (BAL T) (Janeway et al 1999). IgA is the predominant immunoglobulin 
in secretions of the gastrointestinal and respiratory tracts (Galazka 1993 ). IgA in mucosal 
secretions is produced by plasma cells in the submucosal tissue which lie in close 
proximity to the epithelium (Cohen and Heine 1992). In the mucosal epithelial tissue, 
plasma cells lie in close proximity to microfold (M) cells, T lymphocytes and 
macrophages (Brandtzaeg 1989). M cells have a thinner overlay of mucus and may be 
more accessible to luminal antigens than other epithelial cells. Antibody produced at 
mucosa) sites differs dramatically from serum IgA produced in bone marrow. Secretory 
IgA (SlgA) contains a J chain which leads to the formation of an IgA polymer (Breitfeld 
et al 1988). The polymeric IgA binds to a secretory component produced by the 
endoplasmic reticulum before it is excreted across the luminal surface of these cells. The 
functions of SigA involve neutralization of viruses, toxins, enzymes and elimination of 
12 
bacterial plasmids. SigA can block the attachment of antigenic particles to epithelial 
cells, stimulate the alternative pathway of complement, and act in concert with other 
non-specific host defenses (Janeway et al 1999, Russell and Mestecky 1988, Lachmann 
1988). 
2.5 Definitions of a serological response to infection 
The response to primary infection with measles virus (either measles disease or 
measles immunisation) is usually measured by documenting a significant increase in titre 
of IgG antibodies, or by documenting the presence of IgM antibody. At present, no 
serological tests can distinguish between antibodies, whether IgG or IgM, produced by 
measles infection and that produced by immunisation. 
To document a significant increase in antibody titre, paired sera are required: pre
and post-immunisation in the case of response to vaccine, and, in the case of disease, as 
early as possible in the acute phase and l 0-14 days later. The paired specimens should be 
analysed in the same laboratory in the same test procedure, so that variations in test 
conditions do not reduce the comparability of the two results. A significant titre rise is 
generally taken to be a rise in antibody titre by a factor of at least two twofold dilutions 
(fourfold increase) between the first and second specimens (Gershon and Krugman 1979, 
Centers for Disease Control 1982), or a change from undetectable antibody 
(seronegativity) to seropositivity. For example, a change in titre from 16 to 64 or higher 
would indicate seroconversion; a change in titre from 16 to 32 would not be a significant 
increase. While this definition of seroconversion is in common use, some plaque 
neutralisation (PN) tests are so sensitive that persons may demonstrate a fourfold rise in 
antibody titre after immunisation, but have a low post-immunisation titre which may not 
provide long-term protection. 
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The development of very sensitive serological assays such as PN tests has raised 
questions as to the clinical significance of low antibody titres. Although low titres of 
antibody measured by PN assay have been shown to indicate previous exposure to wild 
or vaccine measles virus, there are now data which show that titres below 200 milli­
International Units (mIU) may not be protective. In an outbreak in the USA in 1985, all 
measles cases occurred among college students with pre-exposure antibody titres less 
than 200 mIU. No cases occurred among 71 persons with pre-exposure titres greater than 
200 mIU (Chen et al 1990). 
2.6 Brief history of the development of measles vaccines 
The development of live attenuated measles virus vaccines began soon after the 
isolation of the virus by Enders and Peebles in 1954 (Enders and Peebles 1954). By the 
end of the 1950s, Enders and colleagues had developed the Edmonston B strain of live 
attenuated measles vaccine by subjecting the virus to 24 passages in primary human 
renal cell cultures, 28 passages in primary human amnion cell cultures, and six serial 
chick embryo passages before adapting the virus to chick embryo fibroblasts (Enders 
1962). Because the Edmonston B vaccine was associated with fever greater than 39.5°C 
in 20-40% and rash in approximately 50% of recipients (Krugman et al 1962, 1965), 
gamma globulin was often administered simultaneously to reduce clinical reactions. 
By the middle-late 1960's, new strains of measles vaccine were developed in the 
USA, Japan, Yugoslavia, the USSR and China, by further attenuation of Edmonston 
(AIK-C), Edmonston A (Schwarz), Edmonston B (Moraten, Edmonston Zagreb (EZ)) or 
separate isolates (Leningrad 16, CAM-70). Further attenuation was first achieved by 
Schwarz by 85 additional passages of Edmonston A virus in chick embryo fibroblast 
cultures at 32°C instead of 36-37°C (Schwarz 1964). Although antibody titres attained 
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after further attenuated vaccines such as Schwarz vaccine were lower than those after 
Edmonston B vaccine or natural infection, further attenuated vaccines were associated 
with lower rates of clinical reactions and were suitable for widespread use without the 
need for concurrent administration of gamma globulin. 
One of the first measles vaccines was a formalin-inactivated vaccine derived 
from the Edmonston strain. Usually, three doses of inactivated vaccine or two doses of 
inactivated and one dose of live vaccine were administered at monthly intervals, with 
few side effects (Krugman et al 1965). Use of inactivated vaccine was stopped in 1967, 
when it was realised that immunity was short-lived (Karelitz et al 1963), and that 
recipients were at risk of atypical measles, a presumed hypersensitivity reaction, on 
exposure to live measles virus (Centers for Disease Control 1967). 
2. 7 Measles vaccine potencies
In an attempt to standardise measles vaccine potencies, the Expanded Programme 
on Immunisation established that the minimum quantity of the vaccine virus that should 
be contained in one human dose is generally considered to be 1000 (3.0 log10) viral 
infective units (WHO 1988). However, no maximum potency was specified. Studies 
have shown that the EZ vaccine in potencies of >4.0 log10 infective units per dose was as 
immunogenic in 4-6 month old infants as Schwarz vaccine at 9 months (Whittle et al
1988, Tidjani et al 1989, Markowitz et al 1990, Job et al 1991 ). This lead to use of 
terminology such as "medium" and "high" titre measles vaccines. Vaccine of potency 
between 3.0 and 4.0 log10 was generally considered to be "standard" titre. "High" titre 
was initially defined by WHO as >5.0 log10 and subsequently as >4.7 log10 infectious 
units per dose (Expanded Programme on Immunisation 1990). Intermediate titres were 
described as "medium" titre, although that nomenclature was unofficial (Cutts et al
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1995a). Currently, the official definitions of measles vaccine potencies are "standard" 
titre measles vaccine (those with a potency between 3.0 and 4.6 log,o infectious units) 
and "high" titre measles vaccine (::::4.7 log 10 infectious units) (Bolotovski et al 1994). 
2.8 Brief epidemiology of measles and history of measles vaccination 
The changes in measles epidemiology that occur as immunisation programmes 
mature and their potential implications for measles immunisation policy have been 
reviewed in detail (Cutts 1990). The major changes which occur as high immunisation 
coverage is achieved are an overall reduction in measles incidence rates, a shift in the 
age distribution to older persons, and an increase in the interepidemic interval which may 
lead to the occurrence of outbreaks after a long disease-free period. As high coverage of 
young children is reached and sustained, measles transmission decreases. Cohorts of 
unimmunised children from previous years can then reach older ages without contracting 
measles. The number of susceptible older children gradually builds up so that the 
potential for outbreaks among these children exists. With the introduction and maturation 
of a measles immunisation programme in South Africa, this country has experienced 
these epidemiological changes as well (Epidemiological Comments 1995b). 
2.8.1 Measles epidemiology and history of measles vaccination in developed nations 
Following the introduction of measles immunisation in the USA in 1963, measles 
incidence fell markedly. However, measles incidence fluctuated over the first 10 years as 
monies available for immunisation varied. During the late 1970's, only about 67% of 
children aged l 0-13 years were immunised. In 1976, almost double the number of 
measles cases than that of the preceding 3 years were reported (Mitchell and Balfour 
1985). The age distribution of cases in the USA changed markedly after the introduction 
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of immunisation. Before the introduction of immunisation, only 10% of the cases were in 
persons over 10 years old. In 1976, more than 60% of cases were in individuals greater 
than 10 years of age, with 20 % over 15 years old. 
In 1978 a measles elimination programme was announced, with 3 maJor 
strategies: maintenance of high coverage; mandatory immunisation prior to school entry; 
careful surveillance and aggressive outbreak control. These strategies resulted in a 
further drop in cases. After being close to elimination, with a low of 1497 in 1983, 
reported measles incidence increased since then. This happened despite over 97% of 
children entering school having proof of prior immunisation. Of 152 outbreaks reported 
in 1985 and 1986, IO l occurred mainly among school-aged children. Transmission was 
documented among appropriately immunised children i.e. those immunised at 12 months 
of age or above (Davis et al 1987). 
In response to these school-age outbreaks, the Advisory Committee on 
Immunisation Practices (ACIP) in 1989 recommended more aggressive outbreak control 
measures. During school or college-based outbreaks, all students whose most recent dose 
of vaccine was prior to 1980 were to be reimmunised. In pre-school outbreaks, lowering 
the age at immunisation to 6 months with reimmunisation at 15 months was not effective 
in preventing a rise in measles incidence in 1988 and the first half of 1989. 
Consequently, a recommendation for a routine two-dose schedule, the first at 15 months 
of age and the second at school age, was made in addition to universal immunisation 
during outbreaks (CDC 1989). 
In the United Kingdom, measles vaccination began in 1968 for the vaccination of 
children between I and 2 years of age. The highest incidence of measles continued to be 
in children <5 years old while coverage with the single antigen measles vaccine was only 
50-70% until the mid- l 980s (Miller 1983). There were no special strategies for the first
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20 years until the introduction of MMR (measles, mumps, rubella) vaccine in 1988 with 
a series of public health measures to increase coverage (Cutts and Markowitz 1994). 
There was a sharp decline in the circulation of measles after the introduction of MMR 
vaccine (Ramsay et al 1994). 
In other European countries, such as Sweden, measles vaccination was 
introduced in the early 1970s. Following the experiences in the United States and other 
countries of inadequate protection from measles infection throughout the school period 
or for life with one dose of vaccine, Sweden introduced a two-dose programme of 
vaccination with MMR vaccine in 1982. The vaccination was offered free of charge to 
all children at the age of 18 months and 12 years (Christenson et al 1983). The two-dose 
programme with MMR was later also adopted in Norway, Denmark and Finland. In the 
two and half years since the launch of this programme, the incidence of measles fell by 
93% compared with a normal year before this programme (1982) (Peltola et al 1986). 
2.8.2 Epidemiology of measles and history of measles vaccination in South Africa 
The official measles vaccination programme in South Africa was launched in 
September 1975 with the introduction of free measles vaccine for all children. Prior to 
1975, certain local authorities had, through their own initiative and resources, obtained 
supplies of measles vaccine for inclusion in their immunisation services. However, this 
policy had been implemented only in the larger cities where the prohibitive costs of the 
vaccine were more easily borne (Dick 1975). To further enhance attempts to control 
measles, it was felt that surveillance was necessary. To this end, measles became a 
notifiable condition on 24 August 1979. 
As measles only became a notifiable condition 4 years after the introduction of 
measles vaccination, there is little national data in this country on measles incidence pre-
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immunisation or in the early years of immunisation. In the Municipality of Cape Town, 
with an estimated population of 770780 in 1973, there were 377 admissions to the 2 
large measles referral hospitals (City Hospital for Infectious Diseases, and Red Cross 
War Memorial Children's Hospital) for that year. Thirty three of those admitted died 
(Dick 1975). In South Africa in 1975, there was an estimated 3148 deaths due to measles 
(Epidemiological Comments 1979). 
While notifications generally underestimate the true incidence of a condition, 
including measles, it is nonetheless regarded as a useful tool in outlining the basic 
epidemiology of a condition. Since measles became a notifiable condition, the number of 
notified cases of measles decreased from 19200 in I 980 to I 05 8 in 1998 
(Epidemiological Comments 1995, 1996, 1998 and 1999) (Table 2.1 ). The number of 
notified deaths attributed to measles in this period reduced from 267 to 1. 
While there was an overall decline, this country experienced one of its worst 
recorded epidemics during this period. Although a comparatively low number of cases 
was reported for 1991 (4777 cases) following the launch of the Measles Strategy (a 
period of accelerated immunisation) in 1990 (see later), the number of measles cases 
notified increased dramatically in 1992 to an all-time high of 22745 cases 
(Epidemiological Comments 1995a). The mechanism of such a "post honeymoon" 
epidemic is well described (McLean and Anderson 1988, Cutts et al 1991 ). Rapid 
achievement of high coverage induces a period of low incidence ("honeymoon period"), 
during which older persons are immune from exposure to the natural disease and 
younger persons are immune after immunisation. As the cohorts grow older, while the 
disease incidence is low, most persons acquire immunity from exposure to the vaccine 
rather than to the disease. If coverage is less than 100% and the vaccine is less than 
19 
I 00% effective, susceptible persons gradually accumulate until the epidemic threshold is 
reached, when outbreaks occur ("post-honeymoon period"). 
In the past, measles occurred predominantly in young children(< 5 years old). The< I­
year age showed the highest age-specific incidence at 405 cases/100000. The rate 
declined rapidly with advancing age (Gibson 1982). However, since 1992, there has been 
an upward shift in the ages of those infected with the measles virus (Figure 2.1 ). In many 
of the later outbreaks, school-aged children accounted for a large proportion of the cases 
(Coetzee et al 1994). These were largely also in previously highly vaccinated 
communities. Nationally, the< 5 year olds accounted for 71 % of cases when 
immunisations commenced in 1980 and by 1994 it reduced to 45% (Epidemiological 
Comments 1995a). The changing age distribution of measles i.e. the massive increase in 
incidence of older age-groups compared to younger age groups, as a result of high, 
sustained coverage in many areas, is clearly seen in Table 2.2 and illustrated in Figure 
2.2 
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Table 2.1: Number of notified measles cases and measles deaths in South Africa 
since the introduction of measles vaccination 
Year Cases Deaths 
1980 19193 267 
1981 15809 251 
1982 12906 265 
1983 16735 504 
1984 16160 240 
1985 17884 331 
1986 13459 317 
1987 22559 449 
1988 15258 302 
1989 18268 322 
1990 10624 55 
1991 4777 29 
1992 22745 53 
1993 12870 19 
1994 3820 13 
1995 6826 3 
1996 10604 24 
1997 1422 5 
1998 1058 1 




Unlike developed nations which vaccinated for measles at 15 months or greater 
and could obtain optimal seroconversion due to absence of maternal antibodies, this age 
was too late for developing countries like South Africa. Due to the high incidence of 
measles in children less than one year old, it was recommended in 1975 that measles 
vaccination be given at 9 months of age. Measles vaccination with Schwarz strain was 
unsatisfactory at less than 8 months due to interference by circulating maternal 
antibodies. However, the advent of high-titre EZ vaccine made it possible to vaccinate at 
less than 8 months as it could overcome the effect of the maternal antibodies as it was 
highly immunogenic at 4-6 months (Whittle et al 1988) and had a high protective 
efficacy in children followed up for 2 years (Aaby et al 1988). 
In a study of 20 black South African infants, it was found that the mean measles 
antibody level at 4 months was 192 mIU, 34 mIU at 6 months, and 13 mIU at 9 months 
of age (Kiepiela et al 1991 ). Thus at 6 months, 88% of infants were susceptible to 
measles. Their data supported the WHO recommendation to immunise children in 
developing countries at 6 months with the high-titre EZ measles vaccine, since most 
infants had lost passive immunity against measles by this age. 
From March 1991, children in high-risk areas (low measles immunisation 
coverage (<70%) and reported cases of measles under 9 months of age) received 
0.5ml/dose high titre (5log,0 plaque-forming units [pfu]/dose) Edmonston-Zagreb (EZ) 
vaccine at 6 months of age, and 0.5ml/dose standard titre (4.0log 1 0 pfu/dose) Schwarz 
vaccine at 9 and 18 months. Children in low risk areas (high measles immunisation 
coverage (>70%) and few or no reported cases of measles under 9 months of age) 
received standard titre Schwarz vaccine at 9 and 18 months. In addition, measles 
immunisation status of all children 2-5 years visiting a health-care centre was to be 
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assessed. Those without a definite history of measles vaccination or those who did not 
have 2 doses were to receive measles vaccine (Epidemiological Comments 1993). 
Although EZ vaccine overcame passively transferred maternal antibody better 
than SW strain in comparable doses (Cutts et al 1995a), the WHO recommended that the 
use of high-titre EZ vaccine be stopped following concerns of excess mortality among 
female children who received high-titre EZ vaccine (EPI 1992). Although both EZ and 
SW vaccines showed excess mortality in high-titre vaccine trials, only the high-titre EZ 
vaccine became the target for safety concerns as the high-titre SW vaccine was never 
recommended for routine use by the WHO in the first place (Bennett et al l 999). In line 
with the WHO recommendation, South Africa stopped using high-titre EZ vaccine in the 
above dose in September 1992. The stocks of 0.5 ml high-titre EZ single dose vials were 
returned to the Department of Health stores, re-issued as 5 doses of 0.1 ml/dose and used 
until stocks lasted. Despite epidemiologic, clinical and laboratory studies, a plausible and 
satisfactory biological explanation for the gender differences in mortality due to high­
titre EZ vaccine has yet to surface and its use thus remains halted. 
The current schedule, which is in operation from April 1995, indicates standard 
titre Schwarz (SW) vaccine at 9 and 18 months (Epidemiological Comments 1995). 
2.9 Strategies to control measles 
Many European countries and the United States have instituted a two-dose 
measles-mumps-rubella (MMR) vaccine schedule with the aim of eliminating measles 
and rubella (Peltola et al 1986, Bottiger et al 1987, CDC 1989). The major reason for the 
second dose is to reduce the number of persons susceptible to measles because of a lack 
of response to the first vaccine dose. 
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Countries have adopted the policy of vaccinating children of schoolgoing age, 
either through a routine dose at school entry (Peltola et al 1994, Bottiger et al 1987) or 
through campaigns (EPI 1994, EPI 1995, de Quadros et al 1996). The main reasons for 
this policy are to immunise children who missed vaccination at the age for the first dose 
(failure to vaccinate), and to immunise children who did not respond to the first dose 
(vaccine failures). An additional reason for giving another dose is to boost antibody 
levels in children who responded to the first dose but in whom antibody levels have 
subsequently waned (Markowitz et al 1992). 
Unlike lifelong immunity after natural measles, vaccine-induced immunity does 
not afford a similar duration of protection from exposure to measles virus. In a follow-up 
study by Krugman (1983), 9 of 70 (13%) children vaccinated with Schwarz vaccine had 
undetectable haemagglutination inhibition (HI) antibody levels at 16 years, compared 
with none of 47 children with a history of natural measles. Other clinical and serological 
studies of measles in vaccinated persons suggest that measles antibody levels do not 
persist at protective levels for very long in some individuals. Cases of clinical measles 
have occurred in children known to have seroconverted after vaccination (Mathias et al
1989). Others have documented a rise in measles antibody titre following clinical illness 
in children who had been vaccinated a few years earlier and had seroconverted (Reyes et
al 1987, Zhuj i Measles Vaccine Study Group 1987). Thus, strategies to control measles 
include reimmunisation which seeks to ensure the persistence of antibody levels at or 
above protective levels and avoiding measles infection. 
There have been conflicting results with reimmunisation studies, however. Some 
studies in children with undetectable or low antibody levels after the first immunisation 
have shown no or little antibody responses after reimmunisation (Poland et al 1997, 
Wilkins and Wehrle 1979, Linnemann et al 1982). Other studies, however, have shown 
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that subcutaneous standard titre measles vaccines boost antibody levels among children 
who are seronegative or whose pre-vaccination antibody level is low (e.g. <200 mIU/ml) 
(Wittler et al 1991, Bottiger I 993, Calvert et al 1996, Watson et al 1996). However, 
after an initial antibody response following revaccination of schoolchildren (Deseda­
Tous et al 1978, Markowitz et al 1992) or young adults (Cohn et al 1994 ), antibody 
levels drop again in approximately 40% of children within 1-6 years. 
More than a decade ago, Albert Sabin proposed a radical strategy to prevent 
outbreaks in older children: mass national immunisation campaigns of a broad age range 
of children, irrespective of prior vaccination or disease history (Sabin 1986). In recent 
years, the World Health Organisation has recommended mass campaigns for improving 
measles control in high-risk areas (including refugee camps, urban and peri-urban slums 
and in remote regions with difficult access) (Anon 1994) or on a national scale in 
countries with a measles elimination goal, as in the Americas (de Quadros et al 1996). 
However, scepticism has been expressed about mass immunisation campaigns in this 
country (Barron et al 1987). An extensive mass immunisation campaign, which is not 
followed up by further mass campaigns or strengthening of routine immunisation 
services, can produce an equally extensive epidemic. The reason for this is that a large 
immunisation coverage only temporarily suppresses the transmission of the disease. 
Newborns can then accumulate as susceptible children until disease transmission again 
becomes easy, at which point an epidemic may occur (WHO/UNICEF 1985). Another 
negative aspect of mass campaigns was the diversion of health personnel from normal 
jobs which were consequently neglected. Nonetheless, it has been viewed as being useful 
as the first step along the road towards the acceleration of the EPI, in mobilising people, 
in building community awareness of health and introducing the community to the health 
care system in general and primary health care in particular. Furthermore, surveys of 
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immunisation coverage over time m Mpumalanga Province suggest that current 
immunisation coverage in routine services makes elimination highly improbable by this 
route alone (Durrheim and Ogunbanjo 2000). The high immunisation coverage achieved 
during the mass campaign was not sustained at routine immunisation service level, 
providing support for the complementary approach of combining routine and 
supplementary immunisation for measles elimination. 
All countries in Latin America, and most recently, the United Kingdom and 7 
countries in southern African, have conducted mass vaccination campaigns of children 
under 15 years of age. South Africa has conducted mass campaigns in children <5 years 
old in 1990, 1995 and 2000, while a mass campaign in children 5-15 years old was 
conducted in 1997. In all these campaigns, vaccine had been administered 
subcutaneously. Following earlier studies which showed that measles vaccination with 
aerosols produced good seroconversion (Kress et al 1961, McCrumb 1961, Okuno 1962, 
Ueda et al 1966, Terskikh et al 1971, Danilov 1973), Sabin together with Jorge 
Fernandez de Castro in Mexico, developed simple, inexpensive devices for aerosol 
administration and evaluated the aerosol route in infants (Sabin et al 1983, Sabin et al
1984) and several years later in schoolchildren (Fernandez de Castro and Kumate 1990) 
and found it to be effective. Sabin became convinced of the great potential of the aerosol 
route of mass measles immunisation to increase cost-effectiveness and avoid potential 
hazards of subcutaneous vaccination (Sabin 1991, Sabin 1992). 
2.10 Elimination goals 
Based on the Declaration of Alma Ata in 1978, the World Health Organization 
(WHO) launched the Expanded Programme on Immunisation (EPI), the targets of which 
included " .... a 90% reduction in measles incidence by 1995"). In February 1989 the 
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South African Health Policy Council, under resolutions 8/89 and 9/89, endorsed the 
objectives of the WHO and a "Measles Strategy" was decided upon (Epidemiological 
Comments 1994). This strategy was launched in January 1990. The objective was to 
raise the immunisation levels of all susceptible children against measles (and the other 5 
target diseases) and to maintain these high levels in subsequent cohorts of susceptibles. 
The South African measles goal was set as "reduction of notified cases by 90% and 
deaths from measles by 95% (compared with pre-campaign levels)". Following the 
review of the EPI in South Africa in 1994, the elimination goal was set more specifically 
as: "the reported cases of measles should be reduced to less than 4000 per year for 5 
consecutive years starting in 1996". With the recommendation by the WHO to use mass 
campaigns as a major strategy for measles control and elimination (Expanded 
Programme on Immunisation 1994), it became more important to evaluate the potential 
use of other routes for revaccination, such as aerosol, to make the goal of elimination 
more feasible. 
2.11 Alternative routes of measles immunisation 
While the percutaneous (subcutaneous or intra-muscular) route has been the 
preferred way to administer measles vaccine in routine programmes, other routes may be 
more appropriate for mass vaccination. 
Mass campaigns of percutaneously administered vaccines are much more 
difficult logistically. There is great concern about the potential transmission of infections 
with vaccination by injection, whether in routine programmes or campaigns (Aylward et
al 1995, Simonsen et al 1999). In many developing countries, re-use of syringes is still 
common. This is of great concern in areas of high HIV prevalence, such as many parts of 
Africa. Single-use disposable auto-destruct syringes are recommended for mass 
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campaigns rather than re-sterilisable syringes (Anon 1997). The use of non-reusable 
syringes implies not only an increase in cost, but also a difficulty in ensuring their safe 
disposal, which is particularly evident during campaigns. Administering vaccine by the 
respiratory route avoids these difficulties as well as having the advantages of being non­
invasive, avoids the risk of parenteral transmission of infections, and potentially being 
administered by non-medical staff. 
Vaccination by other routes also needs investigation because of the problem of 
interference by maternal antibodies with percutaneous vaccination at young ages. The 
younger the ages, the poorer the antibody response (Reilly et al 1961 ). In a study of 20 
South African infants, the mean measles antibody levels measured at 4 months was 192 
mIU, 34 rnIU at 6 months, and 13 mIU at 9 months of age (Kiepiela et al 1991). 
Vaccination is hampered because these circulating maternal antibodies neutralise 
conventional Schwarz vaccine. Percutaneous vaccination with Schwarz vaccine at 6 months 
has shown seroconversion of about 60%. Because of this problem, most countries vaccinate 
at ages 9 months and greater. However, in developing countries where vaccine coverage is 
still low or only moderately high, the attack rates are still high for children aged less than 9 
months. In specific areas of South Africa, 20-45% of cases occur in black infants under the 
age of 8 months (Loening 1983). Mucosa) vaccination has been suggested to be effective in 
4-6 month old infants (Sabin et al, 1982, 1983 and 1984, Smerdel 1985, Beck et al 1986). It 
is therefore possible that immunising via the mucosa might enable replication away from 
the interfering effects of maternal antibodies which are confined to the blood. Thus infants 
can be protected effectively before they are at risk of disease (Amler et al 1983). 
Serological responses to measles vaccine after intradermal, conjunctiva!, oral, 
intranasal and aerosol administration showed that the aerosol route was the most promising 
of these non-percutaneous routes of vaccination (Cutts et al 1997). The oral and 
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conjunctiva! routes generally gave poor results, and intradermal administration of vaccine 
using a needle and syringe is more difficult than subcutaneous vaccination. The intranasal 
administration of vaccine gave more variable results than the aerosol route, which gave 
consistently good results in seronegative children. The interference by maternal antibody 
would only apply to primary vaccination and not to booster doses. 
2.12 Aerosol techniques 
Early aerosol techniques utilized a hand-held nebuliser which directed the 
aerosolised vaccine into the open mouth or in front of the mouth and nose (Kress et al, 
1961; McCrumb, 1961 and 1962; Okuno, 1962). Subsequently, the aerosol was 
generated using a compressor with a nebuliser which was held in front of the nose and 
mouth for 30 seconds (Okuno et al, 1965; Ueda et al; 1966). A different technique was 
employed by Terskikh el al (1971) and Danilov (1973) who vaccinated groups of 
children rather than individuals. An ultrasonic generator delivered aerosol in a 12 m3 
room for 20 minutes or a 24 m3 room for 30 minutes where children were allowed to 
play. 
The nebuliser plus compressor technique was later modified with the inclusion of 
a paediatric mask which fitted over the nose and mouth of the child (Sabin et al, 1982, 
1983, 1984 and 1985; Fernandez-de-Castro et al, 1986, 1990). This allowed most of the 
aerosol generated to be inhaled during the 30 seconds of administration. 
The above devices generated particles which were predominantly less than 7 
microns in diameter such that it was more likely to reach the lower respiratory tract. 
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2.13 Effect of measles vaccine strain and aerosol route of administration 
The magnitude and duration of the boosting effect of a second dose of measles 
vaccine in children with low antibody levels may depend on the strain of vaccine and 
route of administration used, in a similar way in which infants respond differently if 
vaccinated with different vaccines when they still have maternal antibody. A review by 
Cutts et al (1995a) of 30 studies conducted on the serological responses to measles 
vaccine in infants less than 9 months showed that seroresponses are higher after EZ and 
AIK-C vaccines than after Schwarz vaccine. Several studies have compared the effect of 
EZ and Schwarz vaccines by subcutaneous injection at the same dose and age, and found 
that EZ vaccine gave superior seroconversion rates to Schwarz vaccine (Khanum et al 
1987, Whittle et al 1988, Tidjani et al 1989, Markowitz et al 1990a, Job et al 1991). In 
aerosol trials of EZ and Schwarz vaccines in infants under 9 months, the seroresponses 
were substantially better with EZ vaccine than with Schwarz vaccine (Sabin et al, 1982, 
1983 and 1984). The estimated retained dose of EZ vaccine in these trials ranged from 
375 to 5000 infectious units per dose. The EZ vaccine is superior to Schwarz vaccine 
even in children who are seropositive. Aerosol administration of EZ vaccine boosted 
antibody levels in a substantial proportion of seropositive children (Sabin et al, 1983; 
Fernandez-de-Castro, 1997), whereas no such boosting was seen with Schwarz 
vaccination in such children (Sabin et al, 1983). 
Most of the early comparative studies of aerosol and subcutaneous routes were 
done in children who had no antibody prior to vaccination. In the studies of Terskikh et 
al (1971) and Danilov (1973), the seroresponses in children receiving aerosol vaccine 
was better (82%-85%) than those vaccinated subcutaneously (72%-76%) for all 3 strains 
(SW, L-16 and USSR-58). Other studies of seronegative children also showed as good as 
or better seroresponses to aerosol than percutaneous vaccination (Kress et al, 1961; 
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Fernandez-de-Castro et al, 1986). The study by Torigoe et al (1986), however, showed a 
poorer response by aerosol due to the children being too young to co-operate in inhaling 
the aerosol. While children in most studies of aerosols were vaccinated for at least 30 
seconds, aerosol vaccinations in the study by Khanum et al (1987) was done for only 10 
seconds. Antibody responses by aerosol in this study were poorer than that by 
subcutaneous vaccination. 
While many of the earlier studies done in seronegative children showed better 
seroresponses following aerosol vaccination compared to subcutaneous vaccination, it is 
also likely that administration of vaccine by the aerosol route could be more effective in 
boosting antibody levels in children who had been previously vaccinated. Two small 
studies of children who had previously received inactivated measles vaccine showed 
better boosting after aerosol of live vaccine than subcutaneous vaccination (Okuno et al, 
1965; Ueda et al, 1966). Other studies have found similar responses between both routes. 
A study in China found comparable responses and duration of immunity after 
revaccination using a local strain of vaccine by either the aerosol or subcutaneous route 
(Dai et al 1991 ). Similarly, administration of EZ vaccine by aerosol has given equivalent 
seroconversion rates to the subcutaneous route in another study (Whittle et al 1984). 
There are theoretical and practical advantages to administering vaccines by the 
aerosol route (Cutts et al l 997). This mimics the natural route of measles infection, and 
could allow vaccine virus to replicate locally on the respiratory epithelium without 
interference from maternal antibody. The aerosol may also be more efficient in 
stimulating the formation of secretory IgA to provide local immunity against re-infection 
(Ogra et al 1980). The aerosol route is particularly suitable for mass vaccination due to 
the ease and rapidity of administration, it's attractiveness to health professionals and 
parents because it is painless, it is non-invasive and avoids the risk of transmission of 
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blood-borne infections such as hepatitis B and HIV associated with vaccination by 
needles, and the cost saving in terms of the saving on expensive single-use needles and 
syringes and the potential for non-medically trained personnel to give the vaccine. While 
especially suited for older children who can actively cooperate, it has also been 
successfully given to infants during a large campaign in Monterrey, Mexico (Sabin et al
1982). In Mexico, several million children have been immunised by the aerosol route, 
which was found to be simple, practical, free of unusual side effects, and with a possible 
superior protective effectiveness as well (Fernandez de Castro et al 1990 and 1997). 
2.14 Effect of acute illnesses on seroresponse 
While measles immunisation of children with acute illnesses in developing 
countries has been shown to be safe and effective (Halsey et al 1985, Ndikuyeze et al
1988), there are differing results on the effect of acute illnesses on seroresponse. A small 
study in the United States found lower seroconversion rates after measles-mumps-rubella 
(MMR) vaccine in 15-18 months old afebrile children with rhinorrhoea compared to 
controls without rhinorrhoea (Krober et al 1991 ). Thirty seven of 4 7 children with 
rhinorrhoea and 50 of 51 children without rhinorrhoea seroconverted at 6-8 weeks post­
immunisation. This is in contrast to large studies conducted in Haiti (Halsey et al 1985), 
where 81 % of infants with rhinorrhoea and 78% of infants without rhinorrhoea 
seroconverted, and in Rwanda (Ndikuyeze et al 1988) where 81 % of ill and 80% of well 
infants seroconverted. 
In a study of l 02 Thai infants who were vaccinated at 9 months of age during the 
season when respiratory illnesses were prevalent, symptoms densities of illnesses at or 
following vaccination were significantly lower among seroconvertors (Migasena et al
1998). In particular, titres were lower in those who had rhinorrhoea when vaccinated and 
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during the first 2 weeks post-vaccination, and diarrhoea in either of the 2 weeks of 
follow-up, compared to those without these symptoms. In contrast, in a randomised trial 
of AIK-C, high-titre or medium-titre EZ measles vaccines in 3.5 and 6 month old infants 
in Zaire, in which the occurrence of rhinorrhoea, cough, diarrhoea, fever, conjunctivitis 
or rash were monitored for 15 days post-vaccination, the seroresponse tended to be 
higher in children with mild illness after vaccination than those without (Scott et al
1999). In the medium-titre EZ group, the proportion of children attaining at least the 
median post-vaccination antibody level was significantly higher in children with 
rhinorrhoea in the first week after vaccination than those without. Significantly higher 
antibody levels in the first week were also seen among children with at least one 
symptom compared with children with no symptoms. Fever on the day of vaccination or 
in the 2 weeks following vaccination did not affect seroconversions or GMTs. Antibody 
levels at 6 months after vaccination showed no consistent differences according to 
presence or absence of symptoms, providing support that mild illness is not a reason to 
delay measles vaccination. Epidemiologic support for this comes from a case series and 
case controlled study by Edmonson et al ( 1996) which did not find any increased risk of 
measles vaccine failure in the respiratory season compared to the summer months. 
In another Thai study where 6 month-old infants were vaccinated with standard 
titre EZ vaccine either subcutaneously or intranasally, most children given vaccine 
subcutaneously seroconverted while few children given vaccme intranasally 
seroconverted. Since upper respiratory infections following vaccination were equally 
common to both groups, upper respiratory infections may have adversely affected 
response to intranasal vaccine (Simasathien et al 1997). 
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2.15 Adverse events following vaccination 
Percutaneous measles vaccination of schoolchildren as a primary or secondary dose 
of vaccine has been conducted for years in many European countries and the United States 
and has been shown to be safe and associated with only minor side effects such as fever and 
occasionally rash. An evaluation of vaccination of schoolchildren in the United Kingdom 
(Roberts 1995) showed that in boys, fever, headache, and rash were more common in 
vaccinees than non-vaccinees (relative risk 2.3, 2.0 and 1.3) respectively); no significant 
increases in symptoms were recorded in girls. Local redness or swelling was reported by 
5% of children. Immunised children were significantly less likely to visit an outpatient 
department than non-immunised children, and there were no differences in general 
practitioner consultations or hospital admissions. 
In a study in India, about 12500 children who were 9 to 15 month were immunized 
with measles vaccine of EZ strain and it was found to be safe (Bhargava et al 1996). Mild 
side effects were documented in 31 % of the children. Of these, 90% were seen in the first 2 
weeks. The commonest side effects were coryza (10%), fever (9.8%), cough (3.2%) and 
diarrhoea (3.2%). Convulsions, with no later sequelae, were documented in 2 cases only. 
This indigenously produced vaccine derived from EZ strain, had a level of reactogenicity 
which was lower than that reported in India with the Schwarz strain. 
In a comparison of standard and medium titre AIK-C, EZ, Leningrad-16 and 
Schwarz strains, the rate of mild adverse events (fever, rash, conjunctivitis, or 
pharyngitis) was low (6-14%) for all strain groups (Bolotovski et al 1994). There were 
no significant differences in adverse events by age, sex, or vaccine titre. 
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In the studies conducted by Fernandez de Castro in Mexico, fewer side-effects 
were reported after aerosol vaccination than those usually seen after subcutaneous 
vaccination (Fernandez de Castro et al I 990 and 1997). 
2.16 Concluding remarks 
Earlier studies involving aerosol measles vaccine have been small and examined a few 
aspects. These studies sometimes gave conflicting results. 
This trial is a large and comprehensive study which aims to expand on the body of 
knowledge in this area by examining the following: 
Effect of route on antibody responses 
Effect of strain on antibody responses 
Antibody responses in the presence of varying levels of pre-existing antibody 
Persistence of antibody over time 
Effect of previous and concurrent illness on seroresponse 
Adverse events following vaccination in vaccines 




Pre-testing of parents' responses, salivary assays and aerosol equipment 
Two pilot studies were done before the main trial at one of the primary schools in Verulam 
(Trenance Park Primary). The first pilot was done to test parents' responses, a salivary 
assay, and logistics. The main purpose of the second pilot was to test the aerosol equipment. 
3.1 PRE-TESTING OF PARENTS' RESPONSES AND THE SALIVARY ASSAY 
The first pilot study was done in February 1996 by a team led by Mr Dilraj and Prof Felicity 
Cutts. 
3.1.1 Objectives 
The objectives of the pilot study were: 
I. To determine the response rate of parents and estimate the proportion of parents that
would consent for the main trial, and to decide whether or not to include children in
grade 5.
2. To estimate the proportion of children with low or with undetectable measles antibody
levels
3. To determine the degree of correlation of antibody levels between blood and saliva
(since it was envisaged that a salivary assay would be used to screen children for low or
undetectable antibody levels).
4. To work out the logistics of the main trial
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3.1.2 Methods 
Prior to determining the response rate of parents at the pilot school, the consent 
form was first tested with about 15 parents at another school (Jhugroo Primary School). 
Concerns raised by some parents related largely to the possibility of transmission of 
HIV, pain to their child and the volume and frequency of blood samples. The consent 
fo1m was subsequently revised to address these concerns in greater detail. 
The revised consent forms explaining the purpose of the pilot study were sent to 
parents/guardians of 480 children in grades I to 5 via the class teachers. The proportion 
of children for whom consents were received was determined. Both blood and saliva 
samples were taken from each child for whom consent was received. 
The saliva was collected using an OraSureR collection device (a small, 
chemically treated absorbent cotton pad with a plastic handle). Actually, oral fluid rather 
than whole saliva was collected. The pad trapped the mucosa) transudate that is produced 
in the gingival crevices. Transudate collected from the general oral mucosa has been 
shown to contain immunoglobulin at concentrations significantly lower than those in 
serum but still well above levels in whole saliva (Gronblad-Saksela 1986). The pad was 
placed between the gum and cheek at the rear of the oral cavity for about 2 minutes. The 
pad was then inserted in the tube containing a preservative solution. It was sealed and 
placed in a cooler box with ice bricks. 
A blood specimen was taken up in a plain vacutainer tube an hour after a local 
anaesthetic cream, EMLA R was applied to the site of venepuncture. The blood samples 
were taken to the MRC in cooler boxes, where it was centrifuged and the sera separated 
and dispensed into duplicate serum storage tubes. 
Both the sera and saliva samples were airfreighted in cooler boxes with icebricks 
to the Public Health Laboratory Services, London, where the assays were conducted. The 
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serum specimens were assayed for measles-specific IgG by using a commercial ELISA 
(Gull Laboratories, Salt Lake City, Utah). Serum specimens found to be negative or 
equivocal by ELISA were subsequently subjected to the plaque-reduction neutralisation 
(PN) assay. The neutralisation test is based on the appearance of plaques in sensitive cell 
culture monolayers due to the growth of measles virus (the "cytopathic effect"). The PN 
assay measures the inhibition of virus activity i.e. reduction in plaque formation caused 
by the neutralisation of measles virus by antibody in the test serum. The PN assay in this 
study was performed using established methods (Brugha et al 1996). In this assay, 
dilutions of sera from each subject were reacted with a standard inoculum of measles 
(challenge) virus. The mixture was added to Vero cells and incubated for 7 days. 
Thereafter, the number of plaques was counted. The dilution of serum reducing the 
number of plaques by 50% was taken as the end point titre. The mIU/ml was calculated 
by direct comparison with the titre of the international reference serum (Forsey et al
I 991 ). Those with antibody levels <200 mlU/ml were considered as seronegative. 
The saliva specimens were assayed for measles specific-IgG using an antibody 
capture radioimmunoassay (RIA) (Perry et al 1993). The radioimmunoassay is a 
competitive binding assay that employs radiolabelled antibody. Polystyrene beads were 
coated with rabbit antibody to human IgG (anti-human IgG) which became irreversibly 
adsorbed to the polystyrene surfaces. The beads were washed and then placed in wells 
and "blocked" by a massive dose of protein (bovine serum albumin) so that all 
subsequent binding events were specific ones due to the antibody rather than to the non­
specific ones due to the bead surface. Saliva samples were added to the wells and the 
antibodies became bound to the anti-human IgG. After incubation and washing, anti­
measles monoclonal antibodies were added, which bound to the antibodies on the bead 




1 labelled anti mouse IgG) was added to the wells. These were then washed to
separate the bound and unbound radioactive material. The bound fraction was then 
counted in a gamma counter to determine the amount of radioactivity. A T:N ratio (ratio 
of bound radioactivity of test sample : bound radioactivity of negative control) of ::::2.1 
was regarded as negative and 2.2-2. 7 as equivocal. 
3.1.3 Results 
3.1.3.1 Response rate 
Consent for specimens to be taken was received for 366 of the 480 children, a response 
rate of76%. 
3.1.3.2 Serum and salivary assays 
Serum samples were obtained from 168 children. By ELISA, 41/168 (24.4%) were either 
negative or in the equivocal range (i.e. 25/168 (14.9%) were negative and 16/168 (9.5%) 
were equivocal). The sera of these 41 children tested by PN showed that only 13 of the 41 
specimens were negative ( <200 mIU/ml) (Table 1 ). 
Table 3.1.1: Measles antibody results in 41 children tested by ELISA and PN assays 
ELISA PN (mIU/ml) 
<200 200 500 500 999 2:1000 
Negative 13 6 6 0 
Equivocal 0 2 11 3 
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positive by saliva RIA. Of 26 specimens that were positive by PN, 18 were negative by 
saliva RIA. 
It is well known that the PN is the most sensitive and specific measles antibody 
assay. Although the ELISA is a less sensitive technique than the PN, it correlated better 
than did the RIA. The RIA produced fewer true negatives and overestimated the 
proportion of negatives to a greater extent than did the ELISA. Because of the poor 
correlation in antibody status between the RIA and PN, the screening phase using a 
salivary assay was dropped from the main trial. 
Originally, we wanted to study children with detectable antibody by PN assay and 
a PN antibody level <500 mIU/ml. However, a study in Mexico showed that 44% of 
children with antibody levels of 500-999 mIU/ml demonstrated a fourfold increase in titre 
after aerosol EZ vaccine. Thus we could include children with antibody levels up to 999 
mIU/ml. In that case, about 23% of children would be included in the follow-up after 
vaccination (all the ELISA negatives and equivocals (i.e. 38/168 from Table 3.1. l )); about 
8% would be seronegative pre-vaccination, and 15% would have levels of 200- l 000 
mIU/ml. Therefore, if we had a total sample size of about 5000 children, we would expect 
about 400 antibody-negative children pre-vaccination and about 750 children with 
detectable antibody levels between 200-1000 mIU/ml. 
The estimated number of children in grades 1-5 in the target study areas was about 
8000. As the proportion that consented in this pilot school was about 76%, including grade 
5, this projection would give a sample size of just over 6000 children. However, it could 
not be predicted that the rest of the proposed schools would also have such a high response 
rate. A more conservative response rate of 60% would give a sample size of 5000 children. 
This sample size would give an adequate number of children to follow up, as calculated 
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above, and also appeared more easily achievable. Thus it was decided to include the grade 
5 children in the main trial. 
The overall conduct of the pilot, the strengths, weaknesses and gaps were noted 
and used in planning the logistics of the main trial. In particular, the role of class teachers 
proved to be very useful. Not only did the teachers assist in distributing the consent forms, 
but also constantly reminded the children to ask their parents to complete and return the 
consent forms. This no doubt played an important part in the high response rate from 
parents. In most classes, the teacher collected the returned forms and had it ready to be 
picked up by the study team. As most teachers could incorporate the above functions into 
their daily tasks easily, these functions were assigned to the teachers in the main trial. 
3.2 PRE-TESTING OF AEROSOL EQUIPMENT 
The second pilot study was conducted in May 1996 by Drs Fernandez de Castro, Mr Dilraj 
and Prof Cutts, primarily to test the aerosol equipment and logistics. 
3.2.1 Objectives 
The objectives of this pilot study were: 
1. To test the overall operation of the aerosol equipment for the local conditions
2. To conduct potency tests of the reconstituted vaccine under local conditions
3. To determine the volume of vaccine administered per dose
4. To work out the logistics of conducting the aerosol vaccination in the main trial
5. To test the understanding of parents/guardians in completing the diary of side-effects
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3.2.2 Methods 
The initial operation of the equipment, potency tests and determination of volume 
of vaccine administered per dose were done at the Medical Research Council (MRC). A 
detailed description and illustration and operation of the aerosol equipment appears in 
Chapter 4.11.3 (Methods) 
As vaccines that were to be used in the main trial had not been sent by the 
manufacturers (SmithKline Beecham, Belgium) at that stage, Edmonston-Zagreb (EZ) 
vaccine produced in Mexico that was brought by Dr de Castro was used in the pilot. For 
potency testing, the lyophilised vaccine was reconstituted in 5 ml diluent and placed in 
the nebuliser on crushed ice. Using a syringe, about 0.5 ml of vaccine was withdrawn 
from the nebuliser before operation of the equipment and after l 0 and 20 simulated 
vaccinations (a simulated vaccination entailed operation of the aerosol equipment for 30 
seconds). The withdrawn vaccines were placed in brown, rubber-stoppered vials, 
wrapped in foil and frozen immediately on dry ice. It was stored at -70
°C and later sent
on dry ice to the Public Health Laboratory Services in London for potency testing. 
Unfortunately, the samples did not remain frozen due to customs delay during shipment and 
a separate simulation of trial conditions was done later (see section 5.3.2). 
Inactivated EZ vaccine was used in the determination of volume of vaccine 
administered per dose. The initial volume of reconstituted vaccine in the nebuliser was 
measured, the equipment operated for 10 minutes, the final/residual volume measured, and 
the volume in a 30 second exposure calculated. 
The logistics of conducting the aerosol vaccination in the main trial was tested at 
the pilot school. This was achieved by doing a dummy run using distilled water in the 
nebuliser. Children from two classrooms were used for this purpose. 
45 
We also took this opportunity to test how well parents/guardians understood the 
covering letter regarding monitoring of side-effects after vaccination and how well they 
completed the diary of symptoms. Parents were requested to fill the diary on a daily basis 
and return the diary 3 weeks after "vaccination". A sample of parents for whom telephone 
numbers were available was also contacted and problems regarding understanding the 
letter and completing the diary were solicited. 
3.2.3 Results 
3.2.3.1 Volume of vaccine administered 
Initial weight of empty nebuliser: 43.01 g 
Weight with 5 ml reconstituted vaccine: 48.26 g 
Therefore, 5 ml of reconstituted vaccine weighed 5.25 g 
 1.05 g/ml 
Weight ofnebuliser with vaccine after 10  minutes operation: 45.46 g 
Weight difference in 10 minutes: 2.8 g 
Weight "used" per 30 second: 0.14 g 
Volume administered per 30 sec  0.14/1.05 
 0.133 ml per dose. 
3.2.3.2 Dose of vaccine administered 
The titre in 0.5 ml of vaccine was 4.621og 1 0 ( or 4.921og, 0 per 1.0 ml) 
(4.62log 10 per 0.5ml = 41686 pfu/0.5ml) 
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= 11088 pfu/0.133 ml 
Approximating the volume to 0.135 ml, the administered dose was thus l 1255pfu/0. l 35 
ml (4.051og JO per 0.135ml). 
3.2.3.3 Diary of symptoms 
Telephonic contact with several parents/guardians revealed that most parents understood 
how to complete the diary. However, quite a few parents were not filling the dairies on a 
daily basis. Most parents were of the working class and cited competing tasks in a short 
period of time in the evenings as the reason for being unable to or forgetting to make an 
entry on a daily basis. 
3.2.4 Discussion and Conclusions 
The aerosol equipment with the transformer worked well. The volume of vaccine 
administered per dose was 0.133 ml (rounded off to 0.135 ml), which is similar to that 
administered by Sabin et al (1983) (0.145 ml). Thus the volume of 0.135 ml delivered a 
dose of 11255 pfu/dose. It is estimated that approximately 25% of the administered dose 
is retained in the lungs (Sabin et al 1983). Thus a 30 second administration of vaccine 
would result in a retained dose of approximately 2814 pfu/dose. This conforms to the 
WHO requirements of a minimum of I 000 pfu/dose stipulated for injected measles 
vaccme. 
The completion of the diary of symptoms by parents/guardians was not optimal. 
For the main trial, it was noted that children would be asked to remind their 
parents/guardians on a regular basis to improve completion of dairies. 
As most children spent the major part of their day at school, observation of the 
children by their class teachers seemed useful in supplementing the information from 
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parents. Thus it was decided that for the main trial, each class teacher would have a list 
of participants where he/she could note what, if any, symptom any of the children 
experienced. 
The overall conduct of the pilot, the strengths, weaknesses and gaps were noted 
and used in planning the logistics of the main trial. 
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CHAPTER4 
Materials, Subjects and Methods 
4.1 MATERIALS 
4.1.1 Office supplies 
Consent forms 
Guidelines for teachers 
Lists of children in each class in each school 
Questionnaires for vaccination and follow-up 
Diaries with guidelines for parents 
Diaries for teachers 
Envelopes for diaries to be stored in on return to schools 
Pre-printed study identity labels: for parent and teacher diaries, questionnaires, 
blood collection tubes, serum storage tubes 
4.1.2 Blood taking and processing 
EMLA R local anaesthetic cream (Astra Pharmaceuticals, Sweden) 
TegadermR patches (3M)/ micropore tape (Millipore) 
Surgical gloves 
Vacutainers tubes and needles 
Cooler box with rack inside 
Sharps disposal box 
Cotton swabs 
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Pipettes in laboratory 
Serum storage tubes (Sarstedt Inc Microtubes, Product no. 72.694.006) and boxes 
Sweets for children 
4.1.3 Vaccination 
4.1.3.1 Subcutaneous vaccination 
1500 doses each of SW and EZ vaccine strain with 0.5 ml vials of diluent 
Clean sheet to put over tables where vaccinating 
Towels to clean tables before and after use 
Needles and syringes 
Cooler box for vaccine and diluent 
Ice pack for vaccine during session 
Sharps disposal box 
Anaphylactic kit (particularly adrenaline and 1 ml syringe) 
4.1.3.2 Aerosol vaccination 
70 vials each of SW and EZ vaccine with 5ml vials of diluent 
Earplugs ( optional for study team) 
Cooler box for crushed ice 
Cooler box for vaccine and diluent 
Stopwatch 
Compressor (Black and Decker AirstationR) 
Stepdown transformer 
Nebulisers and tubing (Aeromist Treatment Set, Cat. No. 4107; Inhalation Plastics 




Sheet to put over table 
Alcohol wipes to clean table 
Towels to clean table after use 
Anaphylactic kit (particularly adrenaline and I ml syringe) 
4.1.4 Examination of child 
Thermometer for each nurse (plus for nurses doing side effect monitoring) 
Tongue depressors: 1 box each school (plus for nurses doing side effect 
monitoring) 
Torch for each nurse (plus for nurse doing side effect monitoring, in case of 
complaint of sore throat) 
Auroscope: I for the team (in case of complaint of otitis) 
4.2 SUBJECTS AND METHODS 
4.2.1 Study design 
The study was a block randomised controlled trial in primary schoolchildren. 
4.2.2 Study population 
To study the effect of a booster dose of measles vaccine, it was ideal for several 
years to have elapsed since the last vaccination in order to allow measles antibody levels to 
wane. Thus, local authorities in the province of KwaZulu-Natal that did not have a policy of 
vaccinating children for measles at schools were targeted. For logistical purposes, the 
Durban and sur ounding districts were favoured. Two local authorities, Verulam and 
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Shallcross, which are on the outskirts of Durban, were chosen on this basis. These two areas 
had a total of 22 primary schools between them with an adequate population size for the 
study. 
Schoolchildren from Class 1 to Standard 2 (grades 1 to 5), corresponding to ages 
between 5 and 14 years, were studied. This age group was selected to minimise loss to 
follow up as it was expected that the majority of the participants would still be in the same 
school at the end of the study period when some children would have entered grade 7. Most 
primary schools do not cater for grades beyond grade 7. Thus, children in the study would 
have to go to various secondary schools, some of which are out of the study area, making 
follow-up difficult. Furthermore, the present primary schools are not usually informed of 
which secondary school the child has moved to. 
4.2.3 Sampling 
All primary schools in the local authorities of Verulam (N=13) and Shallcross 
(N=9) were considered for entry into the study. With the inclusion of children in grade 5, 
preliminary estimates indicated that there would be approximately 8000 children in the 
target classes who would be eligible for initial screening. A conservative estimation from 
the pilot study indicated that consent would be obtained for about 60% of children. Thus, 
approximately 5000 children were expected to be in the study. 
The proportion of children with low or absent antibody levels was not known as 
there were no local data on this. This proportion, however, depended on the age at 
vaccination. According to past vaccination schedules, most of the younger schoolchildren 
would have been vaccinated at 9 months. At this age, around 15% of vaccine failures 
(seronegative children) were expected (Diaz-Ortega et al 1994). Many of the older children 
were vaccinated at 15 months and the proportion of vaccine failures would have been less 
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(Stetler et al, 1986). A study in urban Bolivia found that 30-40% of 2-14 year old children 
had serum antibody levels below 200 mIU/ml, of which around 7% were seronegative 
(Cutts et al, 1995). 
4.2.3.1 Sample size: 
At least 192 children were required to be followed up in each group to detect a 20% 
difference in seroconversion at 2 years after vaccination between any two groups at 90% 
power and 95% significance, assuming 50% seroconversion at 1 month and allowing for 
20% losses and 20% increases for clustering within schools. Therefore, if we had a total 
sample size of about 5000 children, we would expect about 400 antibody-negative children 
pre-vaccination and about 750 children with detectable antibody levels between 200-l 000 
mIU/ml. 
4.2.4 Ethical considerations 
Ethical approval to conduct the study was obtained from the Ethics Committee of 
the University of Natal and the London School of Hygiene and Tropical Medicine. A letter 
of support from the KwaZulu-Natal and National Department of Health (Directorate of 
Communicable Diseases) was also obtained. Permission from the Department of 
Education (KwaZulu-Natal) to conduct the study in this province was sought before 
principals of schools in the selected areas were approached to discuss participation of their 
schools. 
Informed consent was obtained from all parents/guardians. Letters were sent via the 
schools to all parents/guardians of children in the chosen grades. The letter explained the 
purpose of the study, field procedures and possible side-effects, and sought their approval 
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allergy to egg but for whom the detailed information did not suggest a true allergy were 
retained in the study but were observed more closely after vaccination. Children who 
previously reacted adversely to measles vaccine were also excluded. 
4.2.6 Withdrawals 
Parents /guardians were free to withdraw their child from the study at any time in the study 
without having to furnish any reasons. 
4.2. 7 Effect on vaccinators 
Although no effects were seen on people administering the aerosol vaccine in the Mexican 
study, those conducting the aerosol vaccination in this study were asked to note any 
possible side effects as well. Blood samples from all vaccinators were taken before the 
aerosol vaccination phase commenced and one month later to measure any boosting in 
antibody levels. 
4.2.8 Recruitment of schools 
A list of primary schools was obtained from the KwaZulu-Natal education authority and 
contact was made with the principals of all primary schools in the target area (13 schools, 
including the pilot school in Verulam and 9 schools in Shallcross). Mr Dilraj visited each 
school and explained the project to the Principal, the Secretary and teachers, and sought 
their approval and support. Principals were obliged to inform their school governing bodies 
before granting permission. Where requested, school governing bodies and parents were 
addressed to discuss their concerns regarding participation of their schools and children. 
Only one school in Verulam did not participate following refusal by the school governing 
body. Thus 21 schools (including the pilot school) were recruited into the study. 
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4.2.9 Recruitment of subjects 
Information on number of classes from grades 1-5, the internal system of designating 
divisions within each grade, and the enrolment of children in each class were obtained 
from the secretary of each of the participating schools. The corresponding number of 
consent forms was given to each class teacher who distributed it to the pupils. Each 
teacher was also given a set of guidelines to assist the trial team in conducting the study. 
The pupils were asked to hand the forms to their parents/guardians and return the form 
within a week, even if it was unsigned. Parents were asked to send the child's road to 
health card (RTHC) with the completed form. Initially, the entries for measles vaccination 
dates on the consent form were checked by MRC personnel against the Road to Health 
card which was attached, then sent back to children. This created problems when 
returning it to the schools as the child's class was not recorded on it and official names 
on the RTHC sometimes varied from that used at the school. Teachers in each class were 
subsequently asked to check the vaccination dates against cards and give the RTHC back 
to the child immediately, before sending the consent forms to the MRC. 
The schools were revisited one week after consent forms were distributed, to 
make sure the teachers received them and handed them out to the children, and that there 
were no questions. Teachers forwarded the returned forms to the school secretary from 
whom it was picked up by the trial team. The teachers were asked to give the children 
regular reminders to return outstanding forms. Non-responders were also followed up at 
intervals by the trial team. The number of forms that were distributed initially and those 
returned ( consented, refused or unsigned) were noted for each class at all schools. 
When it was apparent that no further consent forms were forthcoming, a database 
was constructed from the information on the returned fom1s. A list of the names and study 
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numbers of each child, by class in each school, was produced (see below section 4.2.10). 
These lists were sent to the schools for verification. 
4.2.10 Coding and assignment of study numbers 
All children for whom consent was received were assigned study numbers. The study 
number was envisioned as a key variable to link the various databases and to glean certain 
information at a glance. The study number was a 5-digit alpha-numeric variable ( eg. 
A0I0l) (Appendix 1). 
The first digit, an alphabet, identified the school. Alphabets were assigned to 
schools in each of the two areas randomly. Verulam schools were assigned alphabets A to L 
and Z, and Shallcross schools were M to U. 
The second and third digits stood for specific classes at each school. Classes were 
arranged in ascending grades and the divisions within each grade were further arranged by 
ascending alphabetic order. Each class was then assigned a sequential number in ascending 
order. The number of classes at the different schools ranged between 6 and 20. 
The last two digits represented the serial number of children within each class. 
Surnames of children were arranged in an alphabetically ascending order and children were 
assigned to an ascending sequential number. The maximum number of children in any one 
class was 35. 
Pre-printed labels with the study numbers were computer-generated in sets for each 
child and used on all questionnaires, blood collection tubes and serum storage tubes. Study 
numbers were suffixed with "a", "b" or "c" for the one month, first and second year follow­
up, respectively, to differentiate samples from that collected at vaccination (baseline). 
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4.2.11 Randomisation 
There were a total of 236 classes at the 20 of the 21 participating schools. The pilot school 
was assigned vaccination differently (see below). Classes at the other 20 schools were 
randomly assigned to one of four combinations of route and strain below using block 
randomisation: 
1. Aerosolised Schwarz measles vaccine (SWae)
2. Aerosolised Edmonston-Zagreb measles vaccine (EZae)
3. Subcutaneous Schwarz measles vaccine (SWsc)
4. Subcutaneous Edmonston-Zagreb measles vaccine (EZsc)
The randomisation was done by Mr Dilraj and Prof Cutts. 
Steps performed in block randomisation: 
1. All schools were listed in ascending alphabetical order with the classes within each
school arranged in an ascending number as assigned (Appendix 1 ).
2. The above combination of vaccine strain and route of administration was assigned a
number from 1-4 (l=SWae; 2=EZae; 3=SWsc; 4=EZsc)
3. All possible combinations of numbers of 1,2,3,4 (Appendix 2) were written down (a total
of 24 combinations). With eyes closed, one investigator twirled a pencil over these
numbers while the other investigator was moving the paper, and the pen-point was
dropped at random on a combination. The other investigator noted the combination and
assigned the sequence to the first 4 classes ( as arranged in step 1 ). The following 4
classes were assigned the sequence as determined by the combination of numbers
obtained next. This process was repeated until all classes in each school were assigned a
number (i.e. a vaccine/route combination). A new sequence was always started for a new
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school. Thus, children received the vaccine/route combination according to the class they 
were in (Appendix 1 ). 
At the pilot school, the antibody status of children had already been determined 
previously in the pilot phase. Only the seronegative children were approached to enter the 
main trial. As relatively few (21/37) seronegative children consented for the main trial, they 
were randomised individually to either EZsc or EZae group. 
4.2.12 Pre-vaccination preparations (April-July 1996): 
The vaccination phase was scheduled to be conducted in the third school term between the 
winter and spring vacations (August to September 1996). Most of the preparations for this 
phase had to be done in the second term (April to June I 996) before schools closed for the 
winter vacation in July. Schools were contacted to check if any activities were being held 
during the third term that might interfere with the vaccinations. These activities included 
tests or examinations, sports, excursions, school photography, and parents' day. Some 
schools had a history of poor attendance on a Monday and Friday, and on the day before or 
after a public holiday. A draft timetable of visits to the schools was drawn up, avoiding the 
above days at those particular schools. At schools where the enrolment was low, two 
schools were scheduled for vaccinations on the same day. The timetable was finalised after 
several rounds of consultation. 
Visits were also made to schools to identify a room or rooms for the vaccination 
phase. The rooms had to be spacious enough to accommodate the vaccination team(s) as 
well as serve as a holding area for the children who have been bled and vaccinated. For 
the subcutaneous vaccination phase, one room was adequate, whereas two rooms were 
needed for the aerosol vaccination phase. This was necessary as to avoid any 
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contamination of children in the holding area who have been bled and vaccinated with 
one strain to inhale vaccine of the other strain done just previously that may have been 
present in the air. 
In this preparatory period, a doctor, a team of nurses and several general assistants 
were recruited for the study. The doctor was responsible for supervising the nurses, act 
appropriately in case of an adverse reaction to the vaccine, and to assist nurses in 
venepunture. The main tasks of the nurses were to conduct clinical examinations, collect 
blood specimens, do subcutaneous vaccination and complete the questionnaires. A week 
before commencement of vaccinations, a training session was held at one of the study 
schools to familiarise the team with the procedures of the trial. This included a discussion of 
the study organisation, questionnaires, venepuncture procedures, vaccination procedures, 
action in case of an adverse reaction to the vaccine and checks to be done to minimise 
errors. Nurses were also trained how to do the follow-up of side-effects. 
4.2.13 Vaccines 
The vaccines for subcutaneous and aerosol vaccination was kindly donated by the 
manufacturer, SmithKline Beecham Biologicals (Belgium). Lyophilised SW and EZ 
vaccines were provided in sealed ampoules with the stabilizers used in routine 
preparations. The vaccine used in both phases were of standard titre, i.e. less than 4.7 log10
(<50120 plaque-forming units [pfu]/dose). The following quantities and information on 
batches was sent by the supplier: 
2000 vials standard titre SW vaccine 1 dose - Lot Ml 74H44 
2000 vials standard titre EZ vaccine 1 dose- Lot MZ13D44 
70 vials of SW vaccine 10 doses ( 100000 infectious units per ml) Lot M 174D 13 
70 vials ofEZ vaccine 10 doses (100000 infectious units per ml) Lot MZ05AA12 
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the viraemic phase 7-14 days after vaccination and cause cross-contamination when they sit 
together in a classroom, or mingle during breaks, and at home where more than one child 
from a family had participated. Thus, the subcutaneous and aerosol vaccination phases were 
conducted approximately two weeks apart. About half the number of classes at each school 
was visited in August and the other half in September, according to the randomisation. The 
subcutaneous phase was coordinated by Mr Dilraj, Dr Cutts and Dr Ahmed, while the 
aerosol phase was coordinated by Mr Dilraj, Dr de Castro and Dr Bennett. 
4.2.14.1 Daily preparations and procedures followed at schools 
Preparations for each school visit were done the previous day. This included packing all 
equipment and supplies for venepuncture and vaccination, anaphylactic kits, labels, 
questionnaires, diaries and chocolates for children. At the beginning of each day, the 
required number of vials of subcutaneous vaccines and diluent would be taken from cold 
room and transported to the school in a cooler box with ice bricks to maintain the cold 
chain. For the aerosol phase, only a few vials of vaccine and diluent were required each day. 
It was thus feasible to keep these in a home fridge overnight. It was also logistically simpler 
to go directly to the school from home instead of diverting to the MRC to pick up the 
vaccmes. 
At the school, a few members of the team prepared the vaccination room while the 
others went to the classrooms. Starting with the lowest grade, in each classroom the team 
was introduced by the team leader and the procedure explained to the class. The names of 
the participants were called out and the questionnaires with their study number already 
affixed were handed to them. In most classes, the teacher assisted in confirming that the 
correct children were identified. A note of absenteeism was made against the relevant name 
on the class list. Information was obtained from teachers (and older children in the higher 
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grades) on a history of illnesses during the previous 4 weeks to assess the effect of recent 
illness on seroresponse to vaccination. Days of absenteeism due to illnesses during this 
period were noted from the class register. A small amount of local anaesthetic cream, 
EMLA R (Astra Pharmaceuticals, Sweden) was applied to the venepuncture site on the 
forearm. Initially about lg  was applied. This was reduced to about 0.2g after several 
children experienced serious side-effects which was thought to be associated with use of the 
cream (see Section 7.4: Adverse events associated with use ofEMLA cream and Discussion 
in Section 7.6). The cream was kept in place with a Tegaderm R patch or a strip of Millipore 
tape. The cream took about an hour for the anaesthesia to become effective. During this 
hour, the above procedure was repeated in each class from grades 1-5. If the cream had 
not been applied to all children after the first hour, some nurses continued with this task 
while the other nurses returned to the vaccination room to commence with collecting 
blood specimens and vaccinations. 
An hour after applying the cream to the first class, sufficient local anaesthesia 
would have been induced in these children for the commencement of blood specimen 
collection and vaccination. 
Children from one classroom at a time were brought to the blood specimen 
collection room by an assistant. The assistant would guide each child to a nurse who 
would first double-check that the child had the correct form by asking their name and 
checking it against that on the form. The nurse noted whether the child was well or had 
any current illness. Children were examined for current upper tract infection (rhinitis, 
cough, conjunctivitis) to assess potential interference with the response to vaccination 
(Krober et al 1991; J. Bennett unpublished data 1995). An oral temperature reading was 
also taken. About 3ml of baseline blood sample was taken up into a plain blood collecting 
tube using a sterile vacutainer needle set. A pre-printed label with the child's study number 
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was fixed to the tube. The nurses recorded on the questionnaire whether or not sufficient 
blood was collected and reasons for failure, when that occurred. 
Up until this point, the above procedures were common to both the subcutaneous 
and aerosol phases. The procedure between the two phases diverged at the next step, the 
administration of the vaccine. For the subcutaneous phase, children remained in the same 
room and received the vaccine after having the blood sample taken. In the aerosol phase, 
children were sent to another room where the vaccination was being conducted, or to their 
classroom if there were any delays with the aerosol vaccination and called later when the 
vaccinators were ready. 
After the blood collection and vaccination for each class was completed, the 
coordinator checked that all questionnaires were collected and that the study number on the 
blood tube matched that on the questionnaire. In the event that mislabelling occurred, blood 
was redrawn from those involved and the first samples were discarded. If the children 
involved could not be located timeously or the attempt at rebleeding was unsuccessful, then 
these children were excluded from the study. During the course of the study, the 
introduction of writing the child's name on the label as well helped to overcome this 
problem. The coordinator recorded all blood specimens collected, unsuccessful bleeds, 
errors if any, refusals, withdrawals and absentees against a master list for each class and 
school. We did not go back to the school on another day to vaccinate absentees. 
4.2.14.2 Subcutaneous vaccination 
Vaccine for subcutaneous injection was provided in single dose vials (0.5ml per dose). 
Each vial of lyophilised vaccine was reconstituted with 0.5ml cold sterile water for 
injection immediately prior to vaccination. After a blood specimen was taken, the child then 
received either the Schwarz or EZ vaccine ( depending on which class was being done) 
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subcutaneously on the upper arm. The subcutaneous injection delivered standard titre doses 
of 12000 pfu/dose for Schwarz vaccine and 10000 pfu/dose for EZ vaccine. Each 
vaccination was done using a sterile disposable needle and syringe. These were disposed 
into sharps containers which were later sent to the incinerators at the King Edward VIII 
Hospital. The vaccine given was also noted on the questionnaire. The vaccinated children 
were given a chocolate to eat and remained for about 15 minutes in a post-vaccination 
observation area in the vaccination room to check that no one experienced any adverse 
reactions to the vaccine. 
4.2.14.3 Aerosol vaccination 
Once children from each class had their blood specimens taken, they were sent to another 
room where the aerosol equipment was set up. Outside the vaccination room, the 
procedure was explained to each group of children and steady breathing demonstrated to 
them. Several children at a time were then sent into the vaccination room. 
The aerosol method and equipment used in this trial has been previously used 
extensively in campaigns in Mexico (Fernandez-de-Castro et al l 990 and 1997). Aerosol 
was generated with a plastic nebuliser (Aeromist treatment set) by passage of pressurised 
air from an electric powered compressor (Black and Decker AirStationR) operating at 30-
40 psi (200-275 kPa) (Figure 4. 1). Both items were kindly supplied by Dr Fernandez de 
Castro. The compressor was designed to operate at 110 volts and a stepdown transformer 
was used to convert the local outlet voltage of 220 volts to 110 volts. The nebuliser was 
kept in a container of crushed ice. A plastic tube, 3 metres long and 5mm in diameter, 
conducted air from the compressor to the nebuliser. A plastic tube, 14 cm long and 2cm in 
diameter, joined the nebuliser to a plastic cone of 8,5 cm maximum diameter, in which 
single-use conical paper cups with the pointed end cut off were inserted as disposable 
65 

masks. The dispersed particles were predominantly <5 microns m diameter 
(manufacturers' data). Being true aerosols rather than a spray, the size of the emitted 
particles mainly targeted the lower respiratory tract. The volume of vaccine delivered 
was estimated in the pilot study with EZ vaccine to be approximately 0.135 ml in the 30 
second burst. The administered doses were thus 14,000 pfu/dose for SWae and 5000 
pfu/dose for EZae. 
The lyophilised vaccme was supplied in 5ml multidose vials. Two vials were 
reconstituted with 10ml of cool diluent and placed in the nebuliser for each round of 
vaccination. One operator kept the mask applied over the nose and mouth of each child, and 
sometimes placed a hand behind the child's head to ensure good contact. A second person 
timed the 30-second exposure to vaccine, switched the compressor on and off, and recorded 
vaccine given, date and other relevant data on the questionnaire. Each vaccinated child had 
a sticker applied to the outer gannent to signify that they had been vaccinated and to avoid 
double exposure to the immunisation procedure. Because of the potential for the 
nebulisation process to inactivate some of the virus during operation of the nebuliser, the 
number of children vaccinated by this route was restricted to 35 from each freshly charged 
nebuliser. A pilot study in Mexico in April 1996 showed little loss of potency with 20-25 
children (titre of 4.42 logs at time O; 4.40 logs at 10 minutes and 4.30 logs at 20 minutes of 
operation of the nebuliser (personal communication : Dr JF de Castro)). As with the 
subcutaneous vaccination, the vaccinated children were given a chocolate to eat and 
remained for about 15 minutes in a post-vaccination observation area in the vaccination 
room to check that no one experienced any adverse reactions to the vaccine. 
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All classes randomised to one of the vaccine strains were vaccinated 
consecutively. To avoid any possible chance of involuntary immunisation by viral particles 
that might theoretically have remained suspended in the air, the same classroom was never 
used for aerosols of more than one vaccine strain. After completing aerosol vaccinations of 
one strain in a classroom, the doors were locked and the teachers were instructed to keep the 
room free of children until the next day. 
Different nebulisers were used for the different vaccine strains. The tubing was 
rinsed between vaccines with distilled water while operating the nebuliser. Used nebulisers 
were sterilized daily by submerging the disassembled parts into very hot water (about 
70°C). Boiling water was not used as it would have deformed the nebulisers. The various 
parts were dried and then assembled and kept in clean plastic bags up to the moment of use. 
The aerosol system was purged with reconstituted vaccine before commencement of 
vaccination each day. When a new nebuliser was used, the system was purged with 
inactivated measles vaccine. 
During the trial, samples of vaccine were taken from the nebuliser at the beginning, 
after 20 and 35 vaccinations of some rounds, frozen immediately on dry ice and sent on dry 
ice for potency analysis at the Public Health Laboratory Services (London). Unfortunately, 
the samples did not remain frozen due to customs delay during shipment, so a separate 
simulation of trial conditions had to be done. 
4.2.15 Follow-up phase 
All children who were seronegative at baseline and a 9% random sample of seropositives 
(see Section 4.2.17) were followed-up at 1 month after vaccination and blood specimens 
collected. 
68 
For the I and 2 year follow-up, the schools were visited a few months before 
specimen collection to incorporate class or school changes. New master lists for each school 
had to be drawn up as there was mixing of children from the old grades to the new grades. 
Where it was possible to locate children who had taken transfer to another school within or 
near the study districts, they were followed-up there. Permission had to be obtained from 
the principal if the school that the child was transferred to was not already participating in 
the trial. 
Unlike the vaccination stage, several attempts were made to obtain blood samples 
from those who were absent on main collection days for all follow-up periods. 
Questionnaires were completed for all children at each follow-up occasion. Information was 
collected on illnesses experienced, visits made to doctors/hospitals and length of 
absenteeism from school during each period. Reasons for loss to follow-up were noted. 
4.2.16 Specimen handling and storage 
Blood samples were placed in racks in a cooler box and transported to the MRC laboratory. 
They were centrifuged and sera separated using a sterile pipette. Sera were separated into 2 
aliquots and dispensed into 2 ml serum storage tubes. The tubes were labelled with pre­
printed labels bearing the study number, placed in a serum storage box with the year and 
school name on it, then stored in a freezer. One set was airfreighted in cooler boxes with a 
sufficient number of ice-bricks to the PHLS in London and the duplicate was kept in 
storage at the MRC. Because of the volume and the need to know the antibody status of 
the children to decide those to be followed-up at I month, the pre-vaccination sera 
collected during August and September 1996 were sent on a weekly basis. The sera 
collected for the I month, I and 2 year follow-up were sent in single batches each of those 
occasions. 
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4.2.17 Laboratory assays 
All pre-vaccination sera were screened for measles-specific IgG using a commercial 
ELISA (Gull laboratories, Salt Lake City, Utah) to determine the baseline antibody 
status. The results were calibrated with the international reference preparation (Forsey et
al 1991) and expressed in mIU/ml. The international reference preparation contains 5 
international units in 1 ml after reconstitution and is run together with the test sera. It is 
used to eliminate inter-laboratory variations and standardize serological assays. The 
ELISA was chosen for baseline antibody determination to enable rapid identification of 
children for the I month follow-up. We aimed to follow-up all children with pre­
vaccination levels of <200 mIU/ml (seronegatives), but only a 9% random sample of 
those with higher levels were followed-up, since serological responses to revaccination 
have previously been reported to be low among children with high antibody levels. 
The serological response to vaccination was measured using the 
Haemagglutination Inhibition (HI) assays (Norrby et al 1962). The HI assay is based on 
the ability of the H protein of the measles virus to bind to erythrocytes, causing a lattice 
of haemagglutinated erythrocytes in the bottom of a tube or well. When serum containing 
measles antibody is incubated with measles virus or purified haemagglutinin prior to the 
addition of red cells, the antibody combines with the haemagglutinin and prevents its 
attachment to red cells (inhibits haemagglutination). The starting dilution was 1 :4 
(approximately 300 mIU/ml), which is slightly higher than that considered protective 
(Samb et al 1995). Children with antibody titres <l :4 were regarded as seronegative by 
this assay even though many probably had low levels of antibody. Sera from the first 
three time points (baseline, 1 month and 1 year after vaccination) were assayed 
simultaneously. Plaque-reduction neutralisation (PN) assays were performed on a 
randomly selected sub-sample of the sera from each group using established methods 
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(Brugha et al 1996). Measles-specific lgM was assayed at one month post-vaccination by 
radioimmunoassay (Perry et al 1993). Detection of lgM antibody was used for the 
classification of subjects as primary responders following vaccination. The assay for IgM 
was identical to that described in Section 3.1.2 for IgG antibody capture 
radioimmunoassay. The exception was that the solid phase beads were coated with anti­
human IgM instead of anti-human IgG. 
The second year follow-up sera were assayed separately. 
The laboratory analyses were done at the Public Health Laboratory Services, London. 
4.2.18 Data collection and management 
Data from the consent forms and questionnaires (vaccination, follow-ups at 1 month, l and 
2 year after vaccination, parents' and teachers' diaries, and absentee forms) were double 
entered using Epilnfo 6.04. The study number was the key variable that was used to link 
and manipulate the various datasets to aid data cleaning. It was necessary to go back to 
schools, parents and the laboratory on several occasions in order to clean the datasets 
sufficiently for analysis. 
4.2.19 Data analyses 
Seroconversion was defined as a four-fold rise in measles IgG antibody level after 
vaccination. Seroconversion with detection of measles specific IgM was considered a 
primary response to vaccination; seroconversion or boosting without measles IgM detection 
was considered as a secondary response. 
Seronegative children were assigned titres of 1 :2 (± 150 mlU/ml). The outcomes between 
the different strains of vaccines and different routes of administration of vaccine were 
compared at 1 month, 1 and 2 year after vaccination by: 
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1) the proportions with at least four-fold titre increases from baseline
("seroconversion ");
2) geometric mean titres (GMT);
3) average fold increase in titres from baseline, analysed on a log transformed scale;
4) proportion of children who were seronegative.
Analyses used EPI-INFO (Dean et al 1994), STATA (Statacorp 1997) and ML3 
(Dalla! et al 1988). Results are presented on an intention-to-treat basis, although 14 
children randomised to receive EZae actually received SWae. 
Chi-square or Fisher's tests were used to assess impact of dichotomous variables on 
seroconversions and seropositivity, and ANOVA (or Mann Whitney U test if non­
parametric) to evaluate effects of variables on geometric mean titres and fold increases. 
Multiple logistic regression was used to analyse seroconversion adjusting for other 
variables. 
The statistical advisor on the trial, Jerry Wheeler, used multi-level modelling to 
determine the proportion of variability at child, class and school levels. Since the 
randomisation to vaccine group was by class, certain analyses were performed using this 
unit of randomisation. The school was also taken into account as an extra component of 




Early responses to Schwarz and Edmonston-Zagreb measles vaccine 
administered by the subcutaneous or aerosol route 
5.1. Overview of chapter 
The emphasis of this chapter is the comparison of serological responses between the 
various groups from baseline to 1 month and I year after vaccination. The results at 2 
years after vaccination are presented separately in the next chapter as fewer subjects 
were followed up at 2 years. This chapter first deals with the recruitment of participants 
and follows up their participation to the end of study period. The baseline characteristics 
of the initial and follow-up participants are described. The chapter touches on the 
problem of potency of the administered vaccine in one of the study arms and how data 
analysis was modified to address this problem. The effect of previous and concurrent 
upper tract infections on seroresponse are also explored. 
5.2. Results 
5.2.1. Recruitment of children and follow-up 
Recruitment of children, numbers followed-up and reasons for loss to follow-up in 
each group are detailed in the Trial Profile (Fig 5.1 ). The trial profile includes follow-up 















I EZae (n= I 028) 
I 530 eligible for follow-up at I month 
57 lost to follow-up 
IO insufficient blood obtained � 
I withdrew consent 
I 462 followed-up at I month 
34 lost to follow-up 
6 insufficient blood obtained 
I withdrew consent +-
5 excluded for other reasons 
416 followed-up at I year 
(385 analysed at I year) 
39 lost to follow-up 
12 insufficient blood obtained I+-
5 withdrew consent 
6 excluded for other reasons 
,, 
323 followed-up at 2 year 
I 8134 invited to participate I 
H 417 refused or withdrew consent before trial I
2730 consent forms not returned 
' 
I 4987 consented I 
512 absent at vaccination or transferred 
34 withdrew consent 
� 26 ineligible due to illness or egg allergy 
88 had insufficient blood taken or refused 
,, 
I 4327 entered into trial I 
+ + I SWae(n= l l 25) I I EZsc (n= l 143) I SWsc (n= I031) 
I 579 eligible for follow-up at I month I I 464 eligible for follow-up at I month I 403 eligible for follow-up at I month I 
47 lost to follow-up 29 lost to follow-up 
16 lost to follow-up 
-+ 15 insufficient blood obtained 5 insuff cient blood obtained I+- -+ 
6 withdrew consent 4 withdrew consent 14 insufficient blood obtained 
, , 
I 511 followed-up at I month I I 426 followed-up at I month I 373 followed-up at I month I 
34 lost to follow-up 21 lost to follow-up I Discontinued I 5 insufficient blood obtained 10 insufficient blood obtained I withdrew consent I+- -+ I withdrew consent 
I I excluded for other reasons 13 excluded for other reasons 
• • 
375 followed-up at I year I 328 followed-up at I year
(326 analysed at I year) (281 analysed at I year) 
28 lost to follow-up 23 lost to follow-up 
6 insufficient blood obtained 
+- -+ 
3 insufficient blood obtained 
9 withdrew consent 4 withdrew consent 
2 excluded for other reasons 4 excluded for other reasons 
'. • 
281 followed-up at 2 year I I 247 followed-up at 2 year
Of the 8134 children who were invited to participate in the trial, parental consent for 4987 
children was received, while 417 refused to participate and forms were not returned by the 
remaining 2730. The outcome of randomisation of the 4987 participants was EZae (1219), 
SWae (1277), EZsc (1302) and SWsc (1189). On the day of vaccination, adequate blood 
samples were obtained from 4327 children who were then vaccinated. Of the remaining 660 
children, 497 were absent, 15 were transferred to schools out of the study area, 34 parents 
subsequently withdrew consent, 81 had insufficient blood obtained, 7 refused to have blood 
taken, 16 were ineligible because of illness and 10 had severe allergy to egg products. 
Of the 4327 children who had a pre-vaccination sample taken, 1976 were eligible for 
follow-up at l month (1740 with pre-vaccination ELISA antibody <200 mIU/ml and 236 with 
2: 200 mIU/ml). Blood was obtained from 1772 (90%) children. Of the 204 remaining children, 
144 were absent at repeated visits, 44 had insufficient blood obtained, 11 were withdrawn by 
parents and 5 had been transferred. 
At l year, samples were collected from 1119 of 1261 children from 3 groups only (EZae, 
EZsc and SWsc - see Section 5.3.2). Of the remaining 142 children, 75 had been transferred, 
14 were repeatedly absent, 21 had insufficient blood obtained, 24 were inadvertently 
vaccinated in the national measles immunisation campaign, 3 were withdrawn by parents, 
died in an accident and 4 were excluded for miscellaneous reasons. 
5.2.2 Potency of vaccine in nebulisers 
The I-month post-vaccination serological results revealed that only 116/511 (22.7%) of 
children given SWae seroconverted. The GMT at 1 month for the SWae group was 1: 11 which 
was substantially lower than that for the other 3 vaccine groups (see later - section 5.3.4.3). 
Subsequently, laboratory simulations of field aerosol conditions showed that the SW vaccine 
had no detectable potency after only a few doses (Fig 5.2), whereas the EZ vaccine remained 
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stable for 40 administered doses (the maximum tested over 20 minutes of operation of the 
compressor). Controls (i.e. reconstituted SW and EZ vaccines kept on ice but not subjected to 
nebulisation) also remained stable over this period. Thus, we concluded that the SW vaccine 
had become inactivated during aerosol administration. As the majority of children in the SW 
group received a vaccine that was deemed largely inactive, any follow-up antibody data at 1 
and 2 years would not have yielded true comparisons with other groups. It was therefore 
considered unethical to collect further blood samples from this group, and further antibody 
tests and analysis were not done on this group. These children (and seronegatives at l year) 
were later offered revaccination by injection. 
5.2.3 Baseline characteristics 
Baseline characteristics are presented for all 4987 children who provided consent (Table 5.1) 
and for the 992 children who had sufficient sera remaining at each timepoint available for 
analysis (Table 5.2). 817 of 992 (82.4%) children had been previously vaccinated. 
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Table 5.2 Baseline characteristics of 992 children analysed 
Characteristic EZae EZsc SWsc p-value
n 385 326 281 
Mean (SD) age (years) 8.4 (I .7) 8.5 (1.4) 8.3 (1.6) 0.06 
Sex - Male(%) 187(49) 146 (45) 149 (53) 0.13 
Race: Indian (%) 287 (75) 249 (76) 214 (76) 0.82 
African(%) 98 (25) 77 (24) 67 (24) 
Prior doses(%): 
I documented I 82 (47) 171 (52) 138(49) 0.59 
::: 2 documented 86 (22) 63 (I 9) 55 (20) 
Undocumented history of::: I dose 47 (12) 42(13) 33 ( I 2) 
No vaccination history 70 ( 18) 50 (15) 55 (20) 
Reported history of measles(%) 124 (32) 111 (34) 85 (30) 0.78 
No measles or vaccination (%) 45 ( 12) 33 ( I 0) 36 (13) 0.58 
Geometric mean HI titre 1:4.4 1:4.3 I :4.2 0.68 
Data are missing for some variables 
Although there were no significant differences between groups by age, sex, race, 
previous measles vaccination or history of measles in the 992 children who were analysed 
(Table 5.2), there were differences in age and those with no measles or vaccination in the 4987 
children who initially consented (Table 5.1 ). There were no significant differences in baseline 
antibody levels between groups by HI (Table 5.2) or in the subset of sera assayed by PN. 
Baseline HI titres did not significantly decrease with age, and did not correlate with a history 
of measles or measles vaccination. 
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On multi-level analysis, there does appear to be some "clustering" of HI response 
within schools, such that 7% of the variation in baseline HI titres is accounted for by 
between-school variation (Table 5.3). This component of variation significantly 
improves the model (likelihood ratio test X2= 6,6; p=0.0 1 ). In the 3 level analysis, there 
was no additional clustering of HI response within classes, after allowing for the school 
level clustering, and the variance estimate for the class component was zero. 
Table 5.3: Proportion of variability in the fold difference at baseline and 1 month at 
child, class and school level, in models of vaccination group including all potential 
confounding variables 
Level Single level analysis Two level analysis: Three level analysis: 
(same as normal linear School + child School+ class+ child 
regression) 
Child 100% 93% 93% 
Class 0% 
School 7% 7% 
5.2.4 Effect of route and strain on serological responses by the different outcome 
measures 
In all groups, antibody levels rose sharply at one month then fell rapidly. 
Responses by the 4 outcome measures are presented below. 
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Average fold increases (95% Cl) 
N 1 month* 1 year** 
385 11.2 (9.9-12.7) 3.7 (3.3-4.l) 
326 6.7 (6.0-7.9) 2.1 (l.9-2.3) 
281 4.7 (4.2-5.4) 1.9 (l.7-2.1) 
EZae vs EZsc and EZae vs SWsc (p<0.001); EZsc vs SWsc (p<0.001)
EZae vs EZsc and EZae vs SWsc (p<0.001); EZsc vs SWsc (p=0.03)
5.2.4.3 Geometric mean titres (GMT) 
The EZae group had highest GMTs at 1 month and 1 year post -vaccination (p:S 
0.001). EZsc had significantly higher titres at l month than SWsc (p<0.001), but the 
difference was of borderline significance at one year (Table 5.6). 
Table 5.6: Geometric mean titres (GMT) at baseline, 1 month and 1 year post­








GMT (95% Cl) GMT (95% CI) GMT(95% CI) 
Baseline 1 month* 1 year 
**
n 
385 1 :4 (4-5) l :50 (45-55) 1:16 (15-18) 
326 1 :4 (4-5) 1 :29 (27-32) 1:9 (8-10) 
281 1:4 (4-5) 1 :20 ( 18-22) 1:8(7-9) 
EZae vs EZsc and EZae vs SWsc (p<0.001); EZsc vs SWsc (p<0.001)
EZae vs EZsc and EZae vs SWsc (p<0.001); EZsc vs SWsc (p=0.04)
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In the 64 children who had PN assays, the GMT at 1 year post-vaccination was 
significantly higher for EZae (3605 mlU/ml) compared to either EZsc (I 345 mIU/ml) or 
SWsc (934 mIU/ml) (p<0.00 l for both comparisons). 
5.2.4.4 Proportion seronegative 
Seronegativity was comparable at about 40% in each group at baseline, and 
virtually no children were seronegative at 1 month (Table 5.7). However, at l year far 
fewer of the EZae group were seronegative (4%) than the EZsc (9%, p=0.009) or SWsc 
( 14%, p=0.001) groups. Among those initially seronegative, seronegativity at 1 year for 
EZae (8%) was also substantially less than for the other 2 groups (19% and 27%, p<0.001 
and 0.004, respectively). 
Table 5. 7: Percentage seronegative at baseline, l month and 1 year post-vaccination 
Vaccine n % seronegative % seronegative % seronegative (95% 
group (95% CI) (95% Cl) CI) 
Baseline 1 month 1 year 
* 
EZae 385 42 (37-47) 1 (0.2-3) 4 (2-6) 
EZsc 326 39 (34-45) 0 (0-1.0) 9 (6-12) 
SWsc 281 46 (40-52) 2 (0.7-5) 14 (10-18) 
I year: EZae vs EZsc (p=0.01); EZae vs SWsc (p<0.001); EZsc vs SWsc (p=0.05) 
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5.2.5 IgM responses 
Only 49 (5 %) of the children mounted an IgM response, suggesting that nearly all 
the children had been previously exposed to measles antigens. lgM responses were 
significantly more frequent among the EZsc and SWsc groups (5.7% and 7.9%) than the 
EZae group (2.5%, p=0.007). 
5.2.6 Effect of pre-vaccination antibody level 
With increasing baseline antibody titres, the magnitude of boosting response at both 
1 month and 1 year decreased (Figure 5.3). The EZae group had greater fold increases at 
baseline titres :=::1:8 at both 1 month and 1 year {p<0.001 for all comparisons with the 
other groups). The EZsc group outperformed the SWsc group at 1 month (p<0.001), but 
fold increases at 1 year exceeded those for SWsc only in those with baseline titres of 1 :4 
{p=0.05). No significant differences between groups were seen at baseline titres :::: 1: I 6 at 
either I month or I year. 
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5.2.7 Multivariate analyses 
With logistic regression, seroconversions in the EZae group were significantly 
more frequent than in either of the other groups at 1 month and 1 year post-vaccination, 
after controlling for baseline titre, race, reported illness in the month before vaccination, 
history of measles or measles vaccination, age and sex (p.:::0.002; Table 5.8). 
African children were significantly less likely to seroconvert than Indian 
children (69% versus 78.9%, p=0.01, Table 5.8). The effect of race remained significant 
after controlling for pre-vaccination antibody level. Regardless of the initial antibody 
level, African children had a lower frequency of seroconversion than Indian children at 1 
month for all baseline line titres (Table 5.9) with an overall statistical significance of 
p=0.003. No significant interactions were noted between race and vaccine group. There 
was no effect on seroresponse of a history of measles, prior vaccine doses, age or sex. 
The GMT at I month was significantly lower (p=0.05) in African children compared to 
Indian children (Table 5.10). 
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Table 5.8: Relationship of selected variables to frequency of at least four-fold 
increases in antibody titres 1 month after booster doses of vaccine 
Number Multivariate 
responding/total Adjusted odds ratio Adjusted p* 
(95% CI) 
Vaccine group 
EZae 326/385 (84.7%) 1.00 
EZsc 257/326 (78.8%) 0.47 (0.29-0.77) 0.002 
SWsc 176/281 (62.6%) 0. I 5 (0.09-0.25) <0.001 
Baseline reciprocal titre 
<4 386/416 (92.8%) 1.00 
4 204/243 (84.0%) 0.33 (0.19-0.58) <0.001 
8 139/207 (67.1%) 0.11 (0.06-0.19) <0.001 
�16 30/126 (23.8%) 0.02 (0.01-0.03) <0.001 
Ethnic origin 
Indian 592/750 (78.9%) 1.00 
African 167/242 (69.0%) 0.51 (0.32-0.81) 0.01 
Illness in month before 
vaccination 
Absent 594/764 (77.7%) 1.00 
Present I 60/222 (72.1 %) 0.57 (0.37-0.90) 0.02 
Measles history 
Absent 457/612 (74.7%) 1.00 
Present 258/320 (80.6%) I .45 (0.95-2.20) 0.08 
Previous vaccine doses 
None reported 133/175 (76.0%) 1.00 
�I 626/817 (76.6%) 1.13 (0.66-2.00) 0.67 
Age when given booster dose 
5-9 years 551/731 (75.4%) 1.00 
10-14 years 203/254 (79.9%) 1.44 (0.90-2.30) 0.12 
Sex 
Female 393/510 (77.1%) 1.00 
Male 366/482 (75.9%) 0.90 (0.62-1.30) 0.59 
*Likelihood ratio statistic. Denominators vary due to missing data for some variables.
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Table 5.9: Percentage seroconversion at 1 month in Indians and Africans stratified 
by baseline titre 
Group Race Baseline titre Overall P 
value 
<4 4 8 >16
All vaccines Indian 93.7 85.8 70.1 28.6 
African 91 77.4 58.5 11.4 0.003 
Subcutaneous vaccines Indian 92.2 82.3 56 25 
African 87.5 68.8 37 4.8 0.002 
EZ Aerosol vaccine Indian 95.9 92.4 90.5 34.3 
African 94.6 90.5 80.8 21.4 0.2 
Table 5.10: GMT at baseline and at 1 month by race 
Race n Baseline 1 month 
Indian 750 I : 4.3 I : 33.4 
African 242 I : 4.6 I : 29.0 
p value 0.45 0.05 
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5.2.8 Effect of recent illnesses on seroresponse 
Seroconversion was significantly reduced in children who reported illness in the 
month before vaccination compared to those without any illnesses (72.1 % versus 77. 7%, 
p=0.02, Table 5.8). No individual symptom in the month before vaccination was 
significantly associated with failure to seroconvert, except fever which resulted in a 
significantly lower proportion of seroconvertors (53/79 (67.1 %) vs 675/874 (77.2%); 
p=0.04). Looking at all symptoms combined, the presence of any of fever, cough, sore 
throat, otitis, or diarrhoea in the month before vaccination was associated with reduced 
seroconversion in the aerosol group (59/78 (75.6%) vs 267/307 (87%); p=0.02) and in 
the subcutaneous group (43/62 (69.4%) vs 390/545 (71.6%). Rhinitis in the month before 
vaccination was associated with reduced response in children receiving subcutaneous 
vaccine (19/28 (67.9%) vs 403/562 (71.7%) but not aerosolised vaccine (31/37 (83.8%) 
vs 274/325 (84.3%)). 
5.2.9 Effect of concurrent upper respiratory tract infections on seroresponse 
There was a reduction in effect (seroconversion) of EZae in presence of rhinitis 
(23/37 (62.2%) vs 196/251 (78.1 %); p<0.05) but not with cough ( 18/28 (64.3%) vs 201/260 
(77.3%)). Titre increases were about 1.5 times higher in those without these symptoms. 
However, the average antibody titre increases in those with these symptoms in the aerosol 
group still exceeded the overall responses in the subcutaneous groups (8 fold vs 6.6 fold 
respectively) 
5.3 Discussion 
We showed that the response to vaccination is better following standard potency EZ 
vaccine delivered by aerosol than EZ or SW vaccine given by subcutaneous injection. As 
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previously reported, antibody levels fell sharply between one month and one year post­
vaccination, but responses remained significantly better in the EZae group at l year, 
when only 4% of children in this group were seronegative. 
The EZae group's response outperformed other groups at pre-vaccination titres 
::::1 :8 (approximately 600mIU/ml). Most of these children had previously been exposed 
to measles or measles vaccine. Other studies have shown 93-100% seroresponse to 
aerosol measles vaccine in seronegative children over 9 months of age (Cutts et al 1997). 
The public health significance of boosting titres to higher levels by aerosol is not yet 
fully clear, but it could indicate a longer duration of increased protection. As large-scale 
measles campaigns are increasingly promoted ( de Quadros et al 1996), the use of a non­
invasive method of vaccination is clearly desirable. If antibody titres are high prior to 
exposure, reinfection is prevented and a boost in titre is rarely seen (Krugman 1977, 
1983, Zhang and Su 1983, Zhuji measles vaccine study group 1987). 
The lower response seen in children who received measles vaccme 
subcutaneously could be related to the fact that the injection is not the usual route of 
entry of measles virus. Some of the injected vaccine could have been neutralised by 
circulating antibodies, blocking replication of vaccine virus (Barry and O'Callaghan 
1997), much like the way measles vaccine is neutralised in infants when circulating 
maternal measles antibodies are present. This probably results in lower stimulation of 
antibody producing cells (Okuno et al 1965). On the other hand, the superior antibody 
response in the aerosol group could be related to the fact that vaccination by aerosol in 
this trial followed the natural route of infection by measles virus. Thus the mucosa! 
surface of the nose, mouth, throat and lungs would be accessible to the vaccine virus. 
Since the size of the aerosol particles were <5 um, most of the vaccine would deposit in 
the peripheral airways (O' Callaghan and Barry 1997). Thus, replication of the vaccine 
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virus would occur over a large surface of the respiratory epithelium. Being removed 
from the neutralising effect of circulating measles antibodies, greater replication of 
vaccine virus would presumably be possible in the mucosa! cells, with a consequent 
greater stimulation of antibody producing cells. The initial replication and antibody 
production at the mucosa! cells would be followed by migration of vaccine virus and 
activated B cells to other tissues via the lymph and blood (Quiding Jarbrink et al 1995) 
where further replication and antibody proliferation would occur. 
Standard titre EZ vaccine performed better than SW vaccine when administered 
subcutaneously, although the differences were much smaller 1 year post-vaccination. In 
young infants, EZ vaccine overcame passively transferred maternal antibody better than 
SW vaccine in comparable doses (Cutts et al 1995a). Our observations suggest that EZ 
vaccine also induces a better response in the presence of actively acquired antibodies. 
Although high titre EZ and SW vaccines were associated with increased mortality 
(Halsey 1993 ), these strains of vaccine are safe at standard titre and are widely used 
(Bennett et al 1999). Current global patterns of vaccine use indicate that millions of 
standard titre doses of both SW and EZ vaccines are used yearly for subcutaneous 
vaccinations, without any of the safety problems previously recognised with high titre 
doses of these vaccines. EZ and SW vaccines are distributed interchangeably for routine 
vaccination programmes in developing countries, according to the tendering procedure 
each year. The differences between subcutaneous EZ and SW vaccine groups, though 
much smaller than those between EZae and either subcutaneous group, may nonetheless 
be important if measles eradication is considered. Further study of strain differences in 
children with pre-existing antibody is needed. 
Antibody profiles probably underestimate protection, smce cellular immune 
responses may be better sustained than antibody titres after revaccination of some 
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Despite a slight reduction in seroresponse in children with concurrent upper 
respiratory tract infections at vaccination in the aerosol group, the antibody responses 
were still superior to that in the subcutaneous group. Studies have shown no or little 
difference in antibody response to measles vaccination in young children with mild 
illness compared to those without any illness at the time of vaccination (King et al 1996, 
Scott et al 1999). Our findings suggest that aerosol vaccination can be conducted in any 
part of the year and that it is not necessary to avoid mass campaigns in the seasons when 
respiratory illnesses may occur more frequently. 
The aerosol route is painless, rapid, non-invasive, practicable for non-medical 
personnel, appears to evoke better humoral immunity, and may also induce superior 
mucosa! immunity. In Mexico, several million children (including infants and 
preschoolers) have been immunized by the aerosol route without unusual side effects 
(Fernandez de Castro et al 1990 and 1997). However, measles vaccines can only be 
recommended for aerosol vaccination when shown to be stable in nebulisers under field 
conditions. The Schwarz vaccine used in this trial lost potency very rapidly in the 
nebuliser, whereas the other vaccine preparations all retained their potency. The reasons 
for the instability of the Schwarz vaccine during nebulisation are being investigated in 
ongoing studies. Concerns about increased hypothetical risks of aerosol vaccine-related 
adverse events (Cutts et al 1997) must be balanced against the real and frequent hazards 
of unsafe injections in developing countries (WHO 1996, Simonsen et al 1999). 
Although improved aerosol delivery technologies, including the development of inhalers 
that might use the stable, lyophilised powder vaccine directly (Li Calsi et al 1999), are 
worth devising, there is favourable experience in Mexico with the equipment and 
approaches used in the South African trial. 
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CHAPTER6 
Persistence of measles antibody 2 years after revaccination by aerosol 
or subcutaneous routes 
6.1 Overview of chapter 
In the previous chapter, we have demonstrated that the response of schoolchildren at 
1 month and 1 year after vaccination was significantly higher after EZ vaccine by aerosol 
than after EZ or SW vaccine by subcutaneous injection. Study of the duration of the 
increase in antibody after revaccination is important, since antibody levels have been 
shown to wane rapidly after revaccination by injection (Watson et al 1996, Bartoloni et
al 1977). In this chapter, we present data on the persistence of antibody at 2 years post­
vaccination and discuss the implications for the use of aerosol vaccination in sustaining 
humoral immunity to measles. 
Sera were collected at 2 years post-vaccination from the EZae, EZsc and SWsc 
groups only. Serum samples were not collected from the SWae because of inactivation of 
the vaccine in the nebuliser (discussed earlier in Section 5.3.2). 
6.2 Results 
Of the 992 children for whom antibody testing was done up to one year, 851 
(86%) were successfully re bled at 2 years post-vaccination. Of the remaining 141 
children, blood was unobtainable from 21 children, 12 were absent at repeat visits, 90 
were transferred to other schools, and 18 withdrew consent. The follow-up history up to 
2 years within each group is detailed in the Trial Profile (see previous chapter - Fig 5.1 ). 
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Among children with pre-vaccination antibody levels below .:::1 :8, most children 
showed a significant (:::fourfold) increase in titre at one month post-vaccination, but titres 
then fell quite rapidly to 1 year. For all groups, the rate of loss of antibody was greatest 
in the first year after vaccination, with geometric mean titres declining substantially more 
slowly in the second year (Fig.6.1 ). 
The initial humoral response to revaccination was of greatest magnitude in the 
EZ aerosol group, and the differences between groups were sustained over time. By 2 
years after revaccination, only 6% of children in the EZae group had reverted to a titre 
below our cut-off of 1:4. The EZsc group was twice as likely (13%, p<0.01), and the 
SWsc group was three times as likely (19%, p<0.001), to have titres below the threshold 
at this time (Table 6.1 ). Seronegativity in the EZsc group was significantly less than that 
in the SWsc group at 2 years (p=0.037). 
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Table 6.1 Comparative serological findings at 2 year after vaccination 
Outcome Vaccine group 
Measure EZae EZsc SWsc 
(n = 323) (n = 281) (n = 247) 
% Seroconversion 55 (49-60) 23 (18-28) 21 (16-26) 
Average fold increase from baseline 3.0 (2.7-3.4) 1.6 (1.5-1.8) 1.5 (1.4-1.7) 
GMT 1:13 (12-15) 1:7.1 (6-8) 1 :6.6 (6-7) 
% Seronegative 5.9 (4-9) 12.5 (9-17) 19 (14-25) 
Amongst those who were seronegative at baseline, seronegativity at 2 years in 
the EZae group (14/134; 10.4%) was substantially lower (p<0.001) than that in the SWsc 
group (34/11 O; 30.9%). While a statistically significant difference between the EZae and 
EZsc groups was seen at I year, this was no longer the case at 2 years (EZsc = 2 I/ 112; 
19%). However, the difference between the EZsc and SWsc groups remained statistically 
significant at 2 years (p=0.05). 
The percentage of children who seroconverted was highest in the EZae group at 
all time points. In the EZae group, 55% (176/323) had seroconverted at 2 years 
compared with only 23% (64/281) for EZsc and 21 % (51/247) for SWsc (p<0.001 for 
both comparisons). At 2 years, the percentage of children with titres > 1 :8 was 
significantly higher in the EZae group (193/323; 59.8%) compared with EZsc (82/281; 
29.2%) and SWsc (64/247; 25.9%), (p<0.001 for both comparisons). 
African children continued to have a lower response than Indian children at 2 years 
after revaccination after controlling for baseline antibody level (Table 6.2). However, 
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African children getting aerosol had significantly better seroconvers1on rates after 
revaccination than the African children getting subcutaneous vaccine (at 1 month: 80% vs 
62%, p=0.005; at 1 year: 52% vs 26%, p<0.001; at 2 year: 38% vs 15%, p<0.001). 
Furthermore, African children vaccinated by aerosol had as good as or significantly better 
seroconversion rates than Indian children vaccinated by injection (at 1 month: 80% vs 74%, 
p=0.33; at I year: 52%vs 31 %, p<0.00 I; at 2 year: 38% vs 24%, p=0.0 1 ). 
At one year after revaccination we had found significant differences in 
serological response by several criteria when comparing EZ vaccine with SW vaccine by 
injection. At 2 years follow-up, however, the differences in seroresponse were much 
smaller and only significant for the proportion of children who became seronegative. In 
addition, children vaccinated at age l 0-14 years were more likely than younger children 
to retain a titre at least fourfold higher than baseline at 2 years post-vaccination. 
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Table 6.2: Relationship of selected variables to frequency of ::::4 - fold increases in 
antibody titres at one month and 2 year after booster doses of vaccine. 
At l month At 2 year 
Percentage Adjusted Adjusted Percentage Adjusted Adjusted 
seroconverting odds ratio p value* seroconverting odds ratio p value* 
Vaccine group EZae 85 1.00 55 1.00 
EZsc 79 0.47 0.002 23 0.16 <0.001 
SWsc 63 0.15 <0.001 21 0.13 <0.001 
Baseline titre <1:4 93 1.00 54 1.00 
(HI) 1:4 84 0.33 <0.001 32 0.34 <0.001 
I :8 67 0.11 <0.001 17 0.09 <0.001 
�1:16 24 0.02 <0.001 3 0.01 <0.001 
Race Indian 79 1.00 38 1.00 
African 69 0.51 0.01 24 0.34 <0.001 
Illness in 
month before absent 78 1.00 41 1.00 
vaccination present 72 0.57 0.02 32 0.67 0.06 
Measles history absent 75 1.00 33 1.00 
present 81 1.45 0.08 36 1.03 0.86 
Prior vaccine none reported 76 1.00 32 1.00 
doses I or more 77 1.13 0.67 35 I.JO 0.71 
Age booster 5-9 years 75 1.00 32 1.00 
dose given 10-14 years 80 1.44 0.12 43 1.84 0.004 
Sex female 77 1.00 35 1.00 
male 76 0.90 0.59 33 0.90 0.58 
* Likelihood ratio statistic.
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6.3 Discussion 
We have found that EZ vaccine administered by aerosol gives better short-term 
responses and better antibody persistence over 2 years post-vaccination compared to EZ 
or SW vaccine by subcutaneous injection. The rate of decline in antibody level flattened 
in all vaccine groups one year after revaccination, suggesting that the differences in 
initial response might have a long-term effect on offering increased protection to 
children who received EZ vaccine by aerosol. Children receiving vaccine by 
subcutaneous injection were 2-3 times more likely to have antibody levels below 300 
mIU/ml at 2 years post-vaccination and also 2-3 times less likely to have HI titres > 1 :8. 
While the majority of children may not develop clinical measles on exposure to wild 
virus, clinical measles has been demonstrated repeatedly among children with antibody 
levels below 125-200 mlU/ml (Chen et al I 990, Samb et al 1995). It has also been 
consistently demonstrated that individuals with antibody titres over approximately 500 
mlU/ml are protected from subclinical infection on re-vaccination (Watson et al I 996, 
Barto Joni et al l 997). The lack of a response to vaccine at baseline HI titres of> I :8 seen 
in this study suggest that there is little or no replication of the vaccine virus, and this 
level of antibody would provide protection against clinical/subclinical infection on 
exposure to wild measles virus in a similar way. Hence it is reasonable to predict that the 
higher the antibody titre, the greater the protection from clinical disease and the lower 
the chance that a child would be involved in measles transmission after exposure to wild 
virus. 
The aerosol route may enhance mechanisms for preventing infection, including 
stimulation of mucosa! immunity. Aerosol particles generated in our study are of a size 
that probably deposit in both the upper and lower respiratory tract. It is therefore likely 
that this route of immunization would elicit a more vigorous mucosa! response than 
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would vaccination by injection. Natural infection by measles virus generally results in 
lifelong immunity. Okuno et al (1965) suggested that the immunity obtained from 
aerosol vaccination was akin to infection immunity and would thus probably be solid and 
durable. The aerosol vaccine given in our trial followed the natural route of infection and 
we have confirmed the suggestion of Okuno by showing that the antibody response was 
better sustained than the injected route. 
The higher antibody titres induced by aerosol may have implications for 
subsequent generations. Antibody titres are lower among persons with vaccine-induced 
compared to natural measles immunity; thus infants born to mothers with vaccine­
induced immunity lose maternal antibody at an earlier age than those born to mothers 
who had measles disease (Lennon and Black 1986, Jenks et al 1988). The level of 
antibody in maternal serum explains almost all the variation in cord antibody titre 
(Gonclaves et al 1999). The administration of vaccine by aerosol to young adults, such 
as in mass catch-up vaccination campaigns, could therefore boost the levels of immunity 
of women in their early childbearing years and provide longer protection to their infants. 
Since countries aiming for measles elimination are changing to a schedule involving 
primary vaccination in the second year of life ( de Quadros et al 1998, WHO 1998), this 
would reduce the chance that a large window of susceptibility would occur in infants 
born to mothers who were vaccinated in childhood. 
Despite ethnic differences, children receiving aerosolised vaccine responded 
better than children receiving vaccine by injection. Thus, the aerosol 1s more 
immunogenic than injection, irrespective of race. 
Age-related differences in response to revaccination usually reflect differences in 
antibody level before revaccination. Since our antibody assay was of low sensitivity, we 





7 .1 Overview of chapter 
The aerosolised EZ vaccine has been shown to evoke a stronger serological 
response after vaccination which has been sustained over a period of 2 years better than 
either of the subcutaneous vaccines. However, immunogenicity on its own is insufficient to 
base recommendations for widespread use of the aerosol route of measles vaccination. 
Acceptability of vaccination by the aerosol route would be further enhanced if the side 
effects are within acceptable limits using subcutaneous vaccination as the standard. 
One of the difficulties with this aspect of the study is that we did not know if the 
symptoms represented a response to the vaccine (which would then be a side effect or 
adverse event) or symptoms of another virus (which would then be a distinct illness). We 
had collected information on measles-like symptoms/illnesses in the acute phase (up to 2 
weeks) and over a longer term (up to 2 years). Symptoms/illnesses experienced in the first 2 
weeks after vaccination are more likely to be due to the measles vaccination than to other 
viruses and are referred to here as adverse events; symptoms/illnesses experienced in the 
first or second year after vaccination are likely to be caused by a range of viruses and are 
therefore referred to here as reported illnesses. 
There has also been concern about the safety of health workers to repeated 
exposures of aerosolised measles vaccine. We have attempted to investigate this issue in 
those involved in conducting the aerosol vaccination. 
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7.2 Methods 
Infonnation on adverse events was measured by various means for the period up to 
2 weeks after vaccination for all those vaccinated in the study, and at 1 month, 1 and 2 year 
in those followed-up. 
On the day of vaccination, all those that were vaccinated were given a diary to be 
completed by their parents/guardians on a daily basis for 2 weeks after vaccination. 
Parents/guardians were asked to tick the column that indicated that the child was well, or 
had one or more specified adverse events (fever, rash, rhinitis, cough, conjunctivitis, 
diarrhoea, other) and to specify the medication given. 
Each class teacher was also given a diary with all the participants' names and study 
numbers. Every schooling day for 2 weeks after vaccination, each teacher was asked to 
record the code of the above-mentioned conditions if he/she noticed whether any child 
experienced one or more of these conditions. 
An objective measure of fever was done by nurses who visited the schools and 
took oral temperature measurements from all children present. While these visits were 
scheduled for day 7 and IO after vaccination, this was difficult due to weekends and 
holidays falling on these days. This was sometimes complicated by poor attendance due 
to teachers' strikes. Thus, temperature readings were done at least once in this period. 
The secretary of each school was contacted daily to check on absentees. Contact 
details of those suspected of being absent due to an illness were obtained from the secretary. 
These children were followed-up by telephone or a home visit by a nurse. A questionnaire 
was completed, noting the reason for absenteeism, symptoms, and whether visits to a doctor 
or hospital were made. 
Longer-tenn infonnation on illnesses was obtained from the children who were 
followed up at I month, I and 2 year after vaccination. These children were asked 
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whether they had been absent from school due to an illness and whether they had 
measles. Those who reported having measles were asked to describe the symptoms. The 
2-year questionnaires included information on hospitalisations.
For some of the analyses of adverse events in the first 2 weeks after vaccination, 
data from the various sources (parents' diaries, teachers' diaries and nurses' follow-up on 
absentees) were combined. The infom1ation from the various sources was not checked 
against each other as it would have been impossible to identify which source was the 
correct one in the event of discrepancies between sources. Since the correctness of 
information from any of the above sources could not be verified, it was assumed that an 
entry for any symptom on any one of the forms from each source was correct. 
For the analysis of adverse events, the SWae group has been included as well. 
Unlike the ethical dilemma that we faced with the collection of blood beyond I month 
from this group, we could and did continue collecting data on adverse events on this 
group for the full duration of the study. Furthermore, information on illnesses was 
collected from children who refused to give blood or from whom blood collection 
attempts were unsuccessful at follow-up. These records have been included in the 
analysis here. 
To investigate any boosting of antibody titres in the vaccinators, a sample of blood 
was taken before the commencement of the aerosol vaccination phase and approximately I 
month later (by which time the aerosol phase was completed). The measles antibody levels 
were measured in these pre- and post- aerosol vaccination specimens. 
In order to attribute any increase in illness rates to vaccination, we needed to get 
some idea of background occurrence of illnesses in the community before, during and in 
the immediate post-vaccination period. We lost an opportunity to utilise the school that 
did not participate in the vaccinations as a control school where background rates of 
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illnesses in the community could be gathered. Thus data on selected conditions were 
gathered retrospectively from a local doctor that served one of the communities where 
the vaccinations were conducted. As the participating doctor served a large section of the 
community and saw a large number of patients, collecting information on illnesses 
retrospectively from one doctor was deemed adequate to determine trends in background 
illnesses. Information on a range of respiratory and related illnesses was collected from 
the records of all patients visiting the doctor between July and October 1996. Actual ages 
were not recorded but patients were classified broadly as adult or child (if of school­
going age). 
7.3 Results 
7.3.1 Adverse events in the 2 weeks post-vaccination 
Information on adverse events in the first 2 weeks after vaccination was obtained 
from 1338 parents' diaries, 2530 records in teachers' diaries and 613 nurses' absentee 
records. One hundred and six children had information from all three sources, 1144 had 
information from two sources and 1763 had information from one source only. 
Combining the information from all of the above 3 sources, a total of 30 I 3 children had 
some information about illnesses from one or more sources. 
Approximately 5% of children had a rash in each group. There were statistically 
significant differences by overall Chi square (tested at the 0.05 level) among groups in 
the proportion of reported fever, rhinitis, cough, headache, sore throat, vomiting and 
otitis (Table 7.1), though the number of reports of vomiting and otitis media were small. 
In almost all of these adverse events with significant differences, the lowest proportion 
was in the SWae group, followed by the EZae group. The number of reported measles 
was low with no significant differences between vaccine groups. Only about one-third 
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(8/22) who reported measles met the CDC criteria for measles (rash and fever and one of 
cough, rhinitis or conjunctivitis). Pre- and 1 month post-vaccination HI titres were only 
available for 2 of these 8 children and both had a 2-fold or greater increase in antibody 
titre. 
Table 7.1: Adverse events reported in the first 2 weeks after vaccination (from 
combined sources) 
Vaccine group 
EZae SWae EZsc SWsc 
Adverse (n=766) (n=637) (n=808) (n=802) 
event No. ill(%) No. ill(%) No. ill(%) No. ill(%) 
Measles 7 (0.9) 7 (I. I) 6 (0.7) 2 (0.2) 
Rash 35 (4.6) 32 (5.0) 40 (5.0) 33(4.1) 
Fever 147 (19.2) 96 (15.1) 180 (22.3) 160 (20) 
Rhinitis 265 (34.6) I 81 (28.4) 335 (41.5) 334 (41.6) 
Cough 224 (29.2) 157 (24.6) 255 (31.6) 226 (28.2) 
Conjunctivitis 45 (5.9) 43 (6.8) 61 (7.5) 51 (6.4) 
DiatThoea 37 (4.8) 36 (5.7) 25 (3.1) 34 (4.2) 
Headache 39(5.l) 22 (3.5) 61 (7.5) 50 (6.2) 
Sore throat 29 (3.8) 23 (3.6) 61 (7.5) 31 (3.9) 
Vomiting 1 (0.1) 3 (0.5) 17 (2.1) 6 (0.7) 
Wheezing 3 (0.4) 2 (0.3) 6 (0.7) 6 (0.7) 















Other information from 1338 parent diaries showed that 462 children took 
medications in the 2 weeks after vaccination, with statistically significant differences 
between groups. Fewer children in the aerosol groups took medications, whether in the 
first week or second week or over both weeks compared to the subcutaneous groups 
(Table 7.2). 
Table 7.2: Number(%) of children who took medications in the 2 weeks after 
vaccination 
Medications Vaccine group p 
taken EZae SWae EZsc SWsc 
(n=352) (n=301) (n=33 I) (n=354) 
In the first week 92 (26. l )  70 (23.3) 119 (36) 99 (28) 0.003 
In the second week 41 (11.6) 39(13) 62 (18.7) 57(16.1) 0.044 
Over both weeks 109(31.0) 87 (28.9) 140 (42.3) 126 (35.6) 0.002 
Information from the absentee records indicated that 344 did not attend school due to 
illness. There was a significant difference (p<0.001) between groups, with both aerosol 
groups having fewer absentees (Table 7 .3 ). A significant difference (p<0.001) between 
groups was also seen amongst those who consulted a doctor (Table 7.3), a substantially 
higher proportion being those in the EZsc group. 
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Table 7. 3: Children absent due to an illness or consulted a doctor in the first 2 weeks 
after vaccination 
Vaccine group 
EZae SWae EZsc SWsc 
(n= l219) (n= l277) (n= l302) (n= l 189) 
Number(%) absent 61 (5.0%) 48 (3.8%) 137 (10.5%) 98 (8.2%) 
Number(%) consulted 5 (0.4%) 4 (0.3%) 41 (3. 1 %) 5 (0.4%) 
a doctor 
Information from the parent diaries and absentee records showed that there were 4 
hospitalisations/visits. All were from the subcutaneous groups with a borderline 
significance between aerosol and subcutaneous routes (0/2497 vs 4/2491, p=0.06). 
An analysis of frequency of adverse events between those who responded to the 
vaccine (responders) and those that did not (non-responders), showed that there were no 
statistically significant differences in the frequency of symptoms between responders and 
non-responders within each of the EZae, EZsc and SWsc groups. In the SWae group 
however, significant differences were seen for conjunctivitis (12/77 vs 8/163; p=0.01), 
headache (4/77 vs 1/163; p=0.04) and rash (10/77 vs 6/163; p=0.015), which occurred 
more frequently in responders (Table 7.4). 
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Table 7.4: Adverse events(%) in responders (R) and non-responders (NR) within each 
vaccine group 
Adverse EZae SWae EZsc SWsc 
Event R NR R NR R NR R NR 
Conjunctivitis 7.9 2.8 15.6 4.9· 7.6 6.9 7.0 8.6 
Headache 6.3 5.6 5.2 0.6· 10.4 6.9 7.9 1.7 
Sore throat 4.0 5.6 3.9 3.7 9.5 10.3 3.7 1.7 
Otitis 0 0 0 0 4.8 0 0 0 
Diarrhoea 5.2 0 5.2 1.8 3.8 0 4.7 6.9 
Vomiting 0.4 0 1.3 1.2 1.9 3.4 0.9 0 
Wheezing 0 0 0 0 1.4 0 0.5 0 
Measles 0.8 0 1.3 0.6 0.9 0 0.5 0 
Fever 25.8 22.2 22.1 14.7 23.7 20.7 24.3 25.9 
Rash 6.0 6.3 13.0 3.7· 5.7 5.2 6.5 8.6 
Rhinitis 36.9 33.3 33.8 27.0 44.l 34.5 52.8 56.9 
Cough 32.9 27.8 29.9 23.9 31.3 32.8 36.0 36.2 
• Statistically significant differences
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7.3.2 Reported illness in the first year 
Five hundred and sixty three of 1647 (34.2%) children reported being absent from 
school due to an illness in the first year after vaccination. Of these, 453 (80.5%) were 
absent for less than a week and 108 (19.2%) for longer than a week but less than a month. 
However, there were no statistically differences between groups for either duration. Only 2 
children were absent due to an illness for longer than a month. Both children were from the 
SWae group, though information on the illnesses was not available. 
One hundred and thirteen (6.9%) children reported having measles in the first year 
after vaccination. Reported measles and symptoms of measles in the 4 groups during the 
course of the first year are presented in Table 7. 5 
Table 7.5: Reported measles and symptoms of measles in the first year after 
vaccination 
Vaccine group 
EZae SWae EZsc SWsc Total 
n=439 n=466 n=392 n=350 N=1647 
Measles 26 (5.9%) 37 (7.9%) 28 (7.1%) 22 (6.3%) 113 (6.9%) 
Rash 20 (4.6%) 25 (5.4%) 26 (6.6%) 17 (4.9%) 88 (5.3%) 
Fever 10 (2.3%) 14 (3.0%) 23 (5.9%) 10 (2.9%) 57 (3.5%) 
Cough 3 (0.7%) 10 (2.1%) 8 (2.0%) 6 (1.7%) 27 (1.6%) 
Rhinitis 2 (0.5%) 4 (0.9%) 2 (0.6%) 4(1.1%) 12 (0.7%) 
Conjunctivitis 3 (0.7%) 0 (0%) 6 (1.5) 3 (0.9%) 12(0.7%) 
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There were no significant differences between groups in the proportion of 
reported measles. Only about half of the children (53/113) reported both rash and fever 
together, though only 24/113 (21%) of reports of measles met the CDC criteria. Of 
61/113 who had HI done at I year, there was a 2-fold or greater increase from baseline in 
41 children. However, comparing antibody titres from the last blood draw atl month to I 
year, it was boosted in only 2 children. Of the 24 children who met the CDC criteria for 
measles, I 1/15 (73%) who had HI done at 1 year had a 2-fold or greater increase in 
antibody titre from baseline but the antibody level was boosted in only l child since the 
last blood draw at I month. 
Forty four of the 113 who reported they had measles said that it was diagnosed by 
a doctor, while 84 children said that it was diagnosed by the parent. For measles 
diagnosed by a doctor, 18/26 (69%) who had HI done at l year had a 2-fold or greater 
increase from baseline, which was similar to that for parents (32/47; 68%). However, 
only I child diagnosed for measles by either a doctor or parent showed any boosting in 
antibody titres from l month to l year. Statistically significant differences between groups 
in the symptoms of measles were only seen for fever (p = 0.03), the highest proportion 
being reported in the EZsc group. Generally, the EZae group had the lowest proportion 
of reported measles or symptoms of measles. 
7 .3.3 Reported illness in the second year 
Five hundred and forty three of 1441 (37.7%) children reported being absent 
from school due to an illness in the second year after vaccination. Of the 543, 438 
(80.7%) were absent for less than a week and 101 (18.6%) for longer than a week but 
less than a month. However, there were no statistically differences between groups for 
either duration. Only 4 children were absent due to an illness for longer than a month, the 
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children being from the EZae, EZsc and SWsc groups. Information was only available 
for the one child from the SWsc group who underwent a circumcision. 
Forty six children visited a hospital in the second year after vaccination for 
illness-related conditions. Of 36 children who were able to provide a diagnosis, the most 
common conditions were wheezing (5), tonsillitis/tonsillectomy (5), bronchitis (3) and 
meningitis (2). There were no statistically significant differences between groups. The 2 
reports of meningitis occurred in the SWae and EZsc groups. 
Sixty four children reported having measles in the second year after vaccination. 
Reported measles and measles symptoms in the 4 groups during the course of the second 
year are presented in Table 7. 6 
Table 7. 6: Reported measles and symptoms of measles in the second year 
after vaccination 
Vaccine group 
EZae SWae EZsc SWsc Total 
n=388 n=403 n=351 n=299 n= l 441 
Measles 14 (3.6%) 17 (4.2%) 13 (3.7%) 20 (6.7%) 64 (4.4%) 
Rash 11 (2.8%) 14 (3.5%) 9 (2.6%) 13 (4.3%) 47 (3.3%) 
Fever 8 (2.1%) 13 (3.2%) 5 (1.4%) 9 (3.0%) 35 (2.4%) 
Cough 6 (1.5%) 7 (1.7%) 5 (1.4%) 7 (2.3%) 25 (1.7%) 
Rhinitis 2 (0.5%) 8 (2.0%) 2 (0.6%) 6 (2.0%) 18 (1.2%) 
Conjunctivitis 3 (0.8%) 4 (1.0%) 0 (0.0%) 5 (1.7%) 12 (0.8%) 
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There were no signifcant differences between groups of measles reported, though 
a lower proportion of measles reports were received from the EZ groups. Twenty six of 
the 64 children reported having both rash and fever but only 17 (27%) met the CDC 
criteria. Of 36 children with HI done at 2 years, 22 had a 2-fold or greater increase from 
baseline. Nine of the 36 (25%) had a boost in titre from year l to year 2. Twenty two of the 
64 who reported they had measles said that it was diagnosed by a doctor while 42 said that 
it was diagnosed by the parent. For those children who had HI done at 2 years, there was a 
2-fold or greater increase in antibody titre from baseline in 8/12 ( 67%) who were
diagnosed by a doctor and 16/24 (67%) who were diagnosed by the parent. A boost in titre 
from year I to year 2 was seen in 3/12 (25%) of doctor-diagnosed measles and 7/24 (29%) 
in parent-diagnosed measles. 
There were no statistically significant differences between the proportions of 
reports of symptoms. 
7.4 Adverse reactions linked to use of EMLA cream 
During the subcutaneous vaccination phase, a few children developed unusual 
adverse reactions. These reactions did not appear to be typical of anaphylaxis following 
measles vaccination. The cases are described below with modifcations done to overcome 
this problem. 
As mentioned in Chapter 4, a mild topical anaesthetic - EMLA R 5% (lidocaine 
25mg per gram/prilocaine 25mg per gram) - was applied to the skin of the antecubital fossa 
of each child at least one hour prior to venepuncture. Approximately I g of this preparation 
was applied and covered with an occlusive dressing. This dose was half of that 
recommended for both adults and children on the product package insert for minor 
115 
dermatological applications such as needle insertion. This reduced dose was selected to 
reduce procurement costs. 
Venepuncture was conducted approximately 2-5 minutes before vaccme was 
administered. Three of the 1648 children on whom the above procedures were performed, 
developed unusual adverse reactions. Two of the adverse reactions occurred in two eight­
year-old boys with no known allergies. Approximately 15 minutes after vaccination with 
subcutaneous Schwarz vaccine, the one child complained of weakness and dizziness, and 
examination revealed no palpable pulse while recumbent with, clammy skin. No urticaria or 
wheezing was noted. He recovered after adrenaline was given. The other boy, from another 
school, displayed similar though less severe symptoms about 10 minutes after receiving EZ 
vaccine subcutaneously. His pulse was slow but palpable, and he too recovered well after 
receiving adrenaline. The researchers later contacted the parents of both boys, who reported 
full recovery from the incidents. 
In another instance, a nine year-old girl with a history of poorly controlled asthma 
but no history of egg allergy, presented similar symptoms about 20 minutes following 
venepuncture and vaccination with subcutaneous EZ vaccine. Unlike the boys, she did not 
fully recover after receiving adrenaline. Although her pulse and initial status did improve, 
about 15 minutes later she began to wheeze markedly and had peripheral cyanosis and 
marked shivering. An intravenous saline drip with 50mg hydrocortisone was administered. 
Following this, the child recovered with no obvious wheezing, but rhonchi were heard on 
auscultation. 
After observing these reactions, which were unrelated to vaccine type and were not 
typical of anaphylactic reactions, we reduced the amount of EMLA by approximately five­
fold and applied about 0.2g to the skin of each child for the rest of the study. No 
subsequent serious adverse events were seen in the remaining 2756 children on whom these 
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procedures were performed (3/1648 vs 0/2756, p=0.05 by Fisher's test) and the topical 
analgesia remained satisfactory. 
Adverse events reporting forms detailing the above events have been completed and 
sent to Astra Pharmaceuticals, the manufacturers of EMLA. 
7.5 Adverse effects on vaccinators 
Pre- and post-vaccination samples were only obtained for 4 of the 6 members who were 
repeatedly exposed to the aerosol. Post-vaccination samples were not obtained for the 2 
international collaborators (NB and JF de C) as they had left South Africa 2 and 3 weeks 
respectively after commencement of aerosol vaccination. The sensitivity of the assay for 
this aspect of the study was l :8. As antibody levels below the level of sensitivity are 
traditionally assigned half this value, the reciprocal antibody level of <8 was assigned a 
value of 4. Though S.H had a post-vaccination reciprocal antibody level of 8 (which 
represented a two-fold increase), there was no significant boosting in antibody titres in the 
vaccinators. None of the vaccinators reported any side effects during or after completion of 
the aerosol vaccination phase. 
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Table 7. 7: Antibody levels in vaccinators at the beginning and after the aerosol 
vaccination phase 
Vaccinator Age Sex Reciprocal antibody titre 
Pre-vaccination Post-vaccination 
A.O. 39 M 64 64 
RS. 19 M 16 16 
S.H. 19 F <8" 8 
N.A. 30 F 16 16 
J.F. de C. 65 M 16 Not done 
J.V.B. 55 M 32 Not done 
• The sensitivity of the assay was 8
7.6 Illnesses in the community 
The total number of patients (both adults and children) seen each month by the doctor 
was 33 7 (July), 425 (August), 409 (September) and 361 (October). Over this 4-month 
period, these patients were diagnosed with (amongst other conditions) asthma (10), 
allergies (20), bronchopneumonia ( 1 ), bronchitis ( 14 ), conjunctivitis ( 4), gastroenteritis 
(34), headache (27), measles (3), otitis media (12), sinusitis (111), tonsillitis (25), upper 
respiratory tract infection (URTI) (230), wheezing (32). For all these conditions, there 
were no statistically significant differences in the frequencies between months. A 
breakdown by month and age-group of the frequency of the most commonly occurring 
illnesses is given in Table 7.8. 
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Table 7.8: Frequency of the most commonly occurring illness in adults (A) and 
children (C) reported by a local doctor in the study area in the month before, during 
and after vaccination 
Month URTI Sinusitis Influenza Wheezing Gastroenteritis 
A C All A C All A C All A C All A C 
Jul 13 11 24 27 2 29 13 2 15 6 I 7 3 2 
Aug 16 27 43 30 7 37 24 1 25 10 3 13 5 1 
Sept 14 29 43 18 6 24 14 4 18 11 2 13 11 5 
Oct 13 24 37 16 5 21 12 l 13 3 6 9 3 2 
7.7 Discussion 
In the first 2 weeks after vaccination, significantly fewer illnesses were reported in 
the aerosol groups. The fewer illness reports in the EZae and SWae groups are supported 
by the lower proportion of children who were absent, took medications or consulted a 
doctor compared to the subcutaneous groups. The differences in absenteeism in the first 2 
weeks due to illnesses were, however, no longer seen in the first and second year after 
vaccination. As the majority of children in this group inhaled vaccine that had become 
inactivated, the SWae group comes closest to being regarded as a control group. It is 
therefore not surprising that the SWae group experienced the lowest proportion of adverse 
events. In addition, those who did have an antibody response to the vaccine (responders) in 
this group had a significantly higher frequency of several adverse events compared to the 
nonresponders. These observations suggest that the reactions seen at 2 weeks were related 







As the subcutaneous and aerosol vaccinations were not conducted concurrently, 
comparison of adverse events by these 2 routes posed a problem. However, the data from 
the local doctor on illnesses in the general community showed that there were no 
statistically significant differences in the frequency of illnesses between the months during 
and around the months that the vaccination by the 2 routes was conducted. This suggests 
that the differences in the frequency of illnesses between the 2 routes can be attributed to 
the route of vaccination. 
It is acknowledged that reports of measles obtained in the manner that we did is not 
totally reliable and that there may have been misdiagnosis of measles. However, it is 
assumed that this would exist across all groups. It would appear that many of the reports of 
measles were incorrect as only about half of the children reporting measles had both rash 
and fever at 1 and 2 year after vaccination. Furthermore, only a fifth to a quarter met the 
additional CDC criteria of accompanying cough or rhinitis or conjunctivitis. In addition, 
not more than a quarter of children reporting measles showed any boosting in antibody 
titre from one time point to the next. 
About one-third of children with measles had their condition diagnosed by a doctor 
while about two-third was diagnosed by parents. The larger proportion of diagnosis made 
by parents is not surprising as the Indian community still clings to many traditional beliefs 
with respect to measles (Dilraj, 1995). While not statistically significant, it is interesting to 
note that the highest proportion of measles was reported by the SWae group in the first 
year after vaccination. This would seem logical as this group would not have been as well 
protected as the other 3 groups. By the same token, the EZae group had the most vigorous 
humoral response to vaccination and thus had the lowest proportion of measles reported. In 
an investigation of a measles outbreak in an area in Mexico where children had been 
previously vaccinated with EZ vaccine subcutaneously and by aerosol, the lowest attack 
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rate was in children receiving aerosol (0.8% of 723), followed by the subcutaneous group 
(14.6% of 48) and unvaccinated children (26.2% of 61) (Fernandez-de-Castro et al, 1997). 
It is well known that there are seasonal variations in the number of measles cases. 
In South Africa, the peak season is in springtime (September-November). The highest 
number of cases has been reported for September, with a mean proportion of 12.3% of 
cases for each year from 1980-1994 (Epidemiological Comments 1995a). Even in 1994, 
the year before our trial, the highest number of cases was recorded in September. Despite 
this, the number of measles reports in our trial was lower in September (aerosol 
vaccination period) than in August (subcutaneous vaccination period), suggesting that the 
lower number of measles reported for the aerosol groups was not due to climatic 
influences. 
With respect to conditions needing a visit to the hospital or hospitalisation, the 
aerosol proved safe in the short and longer term; there were no hospitalisations/hospital 
visits in the aerosol groups (as opposed to 4 in the subcutaneous group) in the first 2 weeks 
after vaccination and the hospitalisations in the second year was not significantly different 
between groups. Concern was also expressed whether aerosol might provoke more serious 
or frequent allergic reactions. As with the others conditions, we did not solicit wheezing 
systematically as a specific symptom, but based on volunteered information, there was no 
significant difference in occurrence of wheezing between the aerosol and subcutaneous 
groups in the first 2 weeks nor by 2 years after vaccination. 
The theoretical concern of cross-contamination ( deposition of organisms in the 
aerosol equipment by infected children and subsequent transmission to healthy children) 
that may result in an increased frequency of illness in children being vaccinated by the 
same aerosol equipment have been raised (Whittle et al, 1984). However, since the first 
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trial of inhaled measles vaccine by Sabin et al (1982) in Monterrey, this procedure has 
been used without any trouble. Almost two decades of experience have elapsed of 
continuous tests and no problem of cross-contamination has occurred. During the 
Mexican epidemic of measles in 1989-90 in which 4 million school children were 
vaccinated by aerosol, a study of side effects in the State of Tabasco demonstrated 
clearly no more adverse reactions with the use of aerosol than with the classic 
subcutaneous route (Fernandez Bracho et al 1990). More importantly, there was not a 
single report of severe illness among the children vaccinated by inhalation in 14 Mexican 
states. Furthermore, Albert Sabin, just a few weeks before his death, approved in a letter, 
the special nebulisers used in this study with the introduction of a very simple 
modification - the use of a corrugated filter paper in the pipe which goes from the 
nebuliser to the nasal-oral pieces of the child, just to avoid the entrance of contaminated 
particles from an individual to the nebuliser content (Sabin AB documents with JF de 
Castro which are available on request). 
The 3 cases of unusual adverse reactions seen during the subcutaneous vaccination 
phase, were not typical vaccine reactions, but were nonetheless of concern. All 3 children 
had previously received measles vaccine and their skin at the application site of the cream 
was intact and free of lesions. The reported rate of anaphylaxis after measles vaccination is 
less than I case per million (CDC 1998). We hypothesize that these reactions may be 
unrelated to the vaccines, but to other factors including: 
1. Emla 5% contains lignocaine and is known to cause allergic reactions, and
in the most severe instances, anaphylactic shock may occur. The dose used
per child contained approximately 25mg lignocaine and 25mg prilocaine.
While there does not appear to have been prior reports of these specific
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reactions (Russell and Doyle 1997), their rarity may have made detection 
difficult in smaller series of patients. 
2. The reactions may have been a response to two traumatic procedures
performed in quick succession, blood collection and vaccination, but they
occurred many minutes after these events and did not appear to be mere faints
nor hysterical reactions.
We suggest that doses substantially lower than those mentioned in the package insert be 
used when topical analgesia in children is induced with lignocaine and prilocaine. 
There have been concerns that aerosol vaccination may be harmful to the 
vaccinators. In his early study with aerosol vaccine, Sabin et al (1983) found that of 3 
vaccinators, one showed a four-fold rise in ELISA antibodies of one person, a two-fold 
rise in another and no change in the third person. We explored the risk to vaccinators 
from repeated exposure to aerosolised measles vaccine over the 3-week period of aerosol 
vaccinations and did not find any significant boosting in antibody titres, nor any overt 
clinical symptoms in any of those conducting the vaccinations. Unbeknown to the one 
team member who had a 2-fold increase in antibody titre, she was actually about 4 
months pregnant at the time of aerosol vaccinations. To this day, her son is a normal, 
healthy child. This suggests that the aerosol vaccine was safe to the foetus. Health care 
workers in many developing countries are repeatedly exposed to wild measles virus 
while caring for sick children, but such exposures have not been recognized as a source 
of harm in immune persons (Cutts et al 1997). 
In conclusion, measles vaccination via the aerosol route was not accompanied by 
any increase in side effects when compared to subcutaneous vaccination. It is therefore 
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safe to the vaccinees. Whilst the number of vaccinators was small, the data suggest that 
aerosol vaccination is safe to the vaccinators as well. 
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CHAPTERS 
Conclusions and recommendations 
In this large randomised controlled trial, we have shown that the responses to 
vaccination with standard potency EZ vaccine administered as an aerosol is superior to 
EZ or SW vaccines administered by subcutaneous injection. While vaccination by 
aerosol using current equipment and formulation is not expected to replace subcutaneous 
vaccination in the standard clinic setting, the findings of this trial has major implications 
for control and elimination of measles using mass campaigns as a major strategy. 
Although Albert Sabin was quite emphatic in the proposal to use aerosols for 
mass campaigns, this was based on his perceptions of cost and convenience issues. 
There were no randomised controlled trials of effectiveness, and his own experience was 
limited to studies in Mexico (with Dr de Castro) and in Brazil in young infants. Although 
Sabin's thoughts were clearly a factor in our ultimately engaging in the present trial, 
several other factors were fundamentally important. First, the concept of national 
campaigns in the control and perhaps ultimate eradication of measles became a reality 
and not just a vision with Ciro de Quadros and the Pan-American Health Organisation 
(PAHO) actually implementing such campaigns and demonstrating its effectiveness in 
controlling and even interrupting measles transmission. Second, Dr de Castro's 
development of "field friendly" methods and his experience and favourable impressions 
of the value and safety of the process in giving doses to over 3 million Mexican school 
children. Third, earlier literature suggested not only that EZ vaccine might perform better 
than SW vaccine, but that booster doses by aerosol might be more effective than 
vaccination by the subcutaneous route. Others also believed that aerosol might be highly 
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effective, in that inducing immunity by the respiratory route might provide superior 
protection. The large number of small studies of aerosol also gives ample testimony of 
the persistent interest and belief of many investigators that this route was worth further 
investigation. 
This trial was the first randomised controlled study, and we would have been in a 
position to endorse the aerosol approach on the basis of obviating HIV/hepatitis B 
transmission and on the wide-scale and apparently safe use in Mexico, convenience, 
acceptance, and cost-effectiveness, even if we simply showed comparable responses of 
aerosol with subcutaneous injection. The superior immunogenicity of the aerosol shown 
in this trial is a major additional incentive to use this approach. 
The factors responsible for instability of nebulised SW vaccine are being 
investigated in ongomg studies. An unappreciated rapid loss of potency during 
nebulisation may be a factor underlying the lesser responses seen rather consistently in 
previous comparisons of SW and EZ aerosols. 
The EZ vaccine has been frequently and unfairly maligned with persons 
frequently believing that EZ vaccine is unsafe, per se. Although both high titre EZ and 
SW vaccines were associated with increased mortality in 5-6 month old infant girls 
compared with receipt of standard doses at 10 months of age for a few years after 
vaccine receipt, both vaccines have a long history of safety in standard doses and have 
been extensively used globally. We have shown in this trial that both the EZ and SW 
vaccine at standard doses to be safe to the vaccinees. 
Concern for the safety of the vaccinators involved in the aerosol vaccination 
phase has been shown to be unfounded in this trial. None of the vaccinators 
seroconverted nor showed any side effects from exposure to vaccine virus that may be 
present around the aerosol equipment. 
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The rate of antibody decline has been suggested to be faster among persons who 
attain the highest antibody levels post-immunisation, so that the range narrows with time. 
In our trial, the EZae attained the highest antibody level l month after vaccination and 
consistently retained a higher level than the other two groups over the 2 year period of 
the trial. Although the EZsc group attained a higher antibody level than the SWsc group 
l month after vaccination, antibody levels declined faster in the EZsc group such that it
was not significantly greater than that of the SWsc group 2 years after vaccination. 
Although seroresponse in HIV-infected individuals has been reported to be lower 
(Palumbo et al l 992), there has been no apparent increase in serious adverse events after 
immunisation at age 9 months in developing countries or at older ages in the USA. The 
only case report of Giant-cell pneumonia in a severely immunocompromised HIV­
infected case happened to a college entrant in the USA who received subcutaneous 
measles-containing vaccine (CDC l 996), and it is probably the atypical host response 
rather than the route that may be important in this. The case was also unusual because the 
patient did not have clinical onset of measles pneumonitis until almost a year after 
vaccination. The patient died about 2 months later with cytomegalovirus (CMV) 
encephalitis as the immediate cause of death and pulmonary measles listed as one of the 
contributing causes. While this case may have been an atypical host response, we still 
need to be careful in giving any live virus by any route to severely immuno­
compromised persons. Studies underway in Malawi and Zambia (high HIV prevalence 
countries) may provide additional data on serious adverse events. Although our 
investigation of measles vaccination by the aerosol route was the largest randomised 
trial, the numbers were still too small to collect information on serious adverse events. 
Agammaglobulinemia, giant cell pneumonia and encephalitis occur in ratios of l: l 000 
measles cases, while subacute sclerosing pan encephalitis (SSPE) occur in ratios of 
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I :300000 measles cases. Other than the case of the college student, there is no evidence 
of any relationship between measles vaccination and the above-mentioned serious 
adverse events. Given the rarity of these conditions following measles illness, concerns 
that aerosol vaccination may lead to one or more of the above serious adverse events will 
be difficult to assess even if aerosol vaccination is in large-scale use. 
As measles control (by current methods) improves, the circulation of wild virus 
will decrease. Thus, persistence of antibody may become shorter because of less 
boosting of antibody titres in immunised persons from exposure to wild virus. In this 
respect, our trial has shown that vaccination by the aerosol route has an added advantage 
in that there is the longer persistence of antibodies after revaccination. 
Some concern was also expressed that children with upper respiratory tract 
infections may not respond adequately to vaccination by aerosol. The superior 
immunogenicity of the aerosolised EZ vaccine despite the presence of upper respiratory 
tract infections adds to the attractiveness of the vaccination by aerosol. This is an 
important consideration in a mass campaign, particularly where staff and time constraints 
may not allow for assessment of upper respiratory tract infections. 
Although observations on adverse events in the first 2 weeks after vaccinations 
were not temporally concurrent by the two routes of immunisation, background illness 
occurrence in the community were similar in both months of subcutaneous and aerosol 
vaccination, enabling conclusions about the reactogenicity of the different routes in our 
trial to be made. It was encouraging to note that significantly fewer side effects occurred 
in the aerosol groups compared to the subcutaneous groups in the 2 weeks after 
vaccination. In the longer term, illness patterns were similar by both routes of 
administration. 
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Although the experience with the equipment and approaches used in this trial 
were favourable, aerosol delivery of measles vaccine can only be put to widespread use 
once it has been licensed for use by this route. The current measles vaccines are only 
licensed for use by injection. The findings of this trial have been presented at the WHO 
meeting of Research Related to Measles Control and Elimination held on 27-29 March 
2000 in Geneva. Aerosol studies with measles-rubella vaccine done in Mexico have 
supported our findings and have encouraged the WHO to recognise the potential of using 
aerosol vaccination in mass campaigns to control and eliminate measles. The WHO has 
therefore placed further research on vaccination by the aerosol route on a high priority 
(Appendix 3). The highest priority issues in this area relate largely to safety issues to 
meet licensing requirements. Subsequent to this meeting, information from existing data 
from our trial has addressed some of the issues (safety to vaccinators and vaccinees). 
Urgent studies in macaques have been recommended and are being undertaken to 
address other safety issues not possible in the trial to fast-track licensing requirements. 
The WHO has also recommended that a meeting of regulatory authorities, companies 
and researchers be convened to clarify steps, time frames and hurdles to bring this 
product to the marketplace. 
Aerosol vaccination using EZ was found to be apparently safe in the age group 
we studied. There is little information on HIV status available for this age group. A 
recent study estimates HIV prevalence to be 5.6% for children 2-14 years old (Nelson 
Mandela/HSRC 2002). However, HIV prevalence was expected to be much lower in 
1996 when the children in this trial were vaccinated. Children who may have contracted 
HIV at birth would have probably not survived to this age. Furthermore, the majority of 
children were not old enough to be sexually active. In this light, the recommendation is 
that aerosol vaccination be done first in children over 5 years of age. Further research of 
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aerosol vaccination m immunocompromised children <5 years old needs to be done 
before aerosol vaccination can be recommended for this age group as well. 
If the measles vaccine is approved for aerosol use by the WHO, then vaccinations 
could be done by a few countries as demonstration projects of the use of aerosol 
vaccination on a large scale with careful monitoring of impact and safety. 
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Appendix 1 
Coding for school, class, vaccine/route codes and child study numbers 
SCHOOL AND CHILD ID NUMBER CODES 
Eg A0IOl 
The child study number is a 5 digit number 
1st digit: letter for school 
2nd and 3rd digits: numbers for class (01.. 15) 
4th and 5th digits: serial number for child in class (01..40 )
CODES 
A Dawncrest 
A0 l Class IA AE 2 
A02 Class 1 B SC 3 
A03 Class 2A AE I 
A04 Class 2B SC 4 
AOS Std IA SC 4 
A06 Std IB SC 3 
A07 Std 2A AE I 
A08 Std 2B AE 2 
A09 Std 2C AE I 
AI 0 Std 3A SC 3 
Al I Std 3B AE 2 
B Everest Heights 
B0 l Class IA AE2 
B02 Class IR SC4 
B03 Class IS SC3 
B04 Class 2K AE I 
BOS Class 2P AE2 
B06 Std 10 SC4 
B07 Std IS AE I 
B08 Std IM SC3 
B09 Std 2A AE I 
BIO Std 2N AE2 
Bl I Std 2T SC4 
Bl2 Std 3K SC3 
Bl3 Std 3R AE I 




GOI Class IA SC 3 
G02 Class I B SC 4 
G03 Class 2A AE 1 
G04 Class 2B AE 2 
GOS Std IA AE 1 
G06 Std lB SC 3 
G07 Std 2A SC 4 
G08 Std 2B AE 2 
H Verulam Madressa 
HOl Class IA AE 2 
H02 Class l B AE 1 
H03 Class 2A SC 4 
H04 Class 2B SC 3 
HOS Std IA AE 2 
H06 Std lB SC 3 
H07 Std 2A AE 1 
H08 Std 2B SC 4 
H09 Std 2C SC 4 
HlO Std 3A AE 2 
Hll Std3B AE 1 
I Verulam Primary 
l01 Class IA AE 1 
l02 Class I B AE 2 
l03 Class 2A SC 4 
l04 Std IA SC 3 
IOS Std lB SC 3 
l06 Std 2A AE 1 
l07 Std 2B SC 4 
J Acacia 
JOI Class IA AE 1 
J02 Class 1 B SC 4 
J03 Class 1 C AE 2 
J04 Class 1 D SC 3 
JOS Class 2A SC 4 
106 Class 2B AE 1 
107 Class 2C SC 3 
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JO8 Std IA AE 2 
JO9 Std 1B SC 3 
JlO Std IC SC 4 
Jl I Std 1D AE 1 
J12 Std 2A AE 2 
J13 Std 2B AE 2 
J14 Std 2C SC 4 
J15 Std 2D SC 3 
JI6 Std 3A AE I 
J17 Std 3B AE 1 
J18 Std 3C AE 2 
J19 Std 3D SC 4 
K Parkgate primary 
Class IA AE 2 
Class IS AE I 
Class 2 SC 4 
Std IA SC 3 
Std 2 SC 3 
Std 3R SC 4 
Std 3S AE 2 
L Dianthus 
LOI Class IA SC 4 
LO2 Class I B SC 3 
LO3 Class 2A AE 2 
LO4 Class 2B AE I 
LOS Std lA AE 2 
LO6 Std 1B AE 1 
LO7 Std 2A SC 3 
LO8 Std 2B SC 4 
LO9 Std 3A SC 4 
LIO Std 3B (No reply) 
LI I Std 3C AE 2 
LI2 Std 3D AE I 
M Everes t (Shallcross) 
MOI Class IA SC 4 
MO2 Class l B Ae I 
MO3 Class l C SC 3 
MO4 Class 2A AE 2 
MOS Class 2B AE l 
MO6 Std lA AE 2 
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P08 Std lG SC 3 
P09 Std IN AE 1 
PIO Std 2B AE 2 
P 11 Std 2M SC 3 
P12 Std 2N SC 4 
P13 Std 2R SC 4 
Pl4 Std 3C AE 2 
P15 Std 3G AE l 
P16 Std 3R SC 4 
P17 Std 3P SC 3 
Q Marianpark 
QOl Class IA SC 4 
Q02 Class l B AE 2 
Q03 Class 1 C AE 1 
Q04 Class 1 D SC 3 
Q05 Class 1 E AE 1 
Q06 Class 1 F SC 3 
Q07 Class 2A SC 4 
Q08 Class 2B AE 2 
Q09 Class 2C AE 2 
QlOStd IA AE 1 
Q 11 Std 1 B SC 3 
Q12StdlC SC 4 
Ql3 Std ID SC 3 
Q14 Std 2A AE 1 
Q15 Std 2B SC 4 
Q16 Std 2C AE 2 
QI 7 Std 3A AE 1 
Q18 Std 3B AE 2 
Q19 Std 3C SC 3 
Q20 Std 3D SC 4 
R Parklands 
ROI Class IA SC 3 
R02 Class 1 B AE 2 
R03 Class l C AE I 
R04 Class 2A SC 4 
ROS Class 2B AE 2 
R06 Std IA SC 3 
R07 Std 1B AE l 
ROS Std IC SC 4 
R09 Std 2A AE I 
RIO Std 2B SC 3 
Rl I Std 2C AE 2 
160 
S Shallcross primary 
SOI Class IA SC 3 
SO2 Class I B AE 2 
SO3 Class 2A SC 4 
SO4 Class 2B AE 1 
SOS Std lA SC 3 
SO6 Std 1B AE I 
SO7 Std 2A AE 2 
SO8 Std 2B SC 4 
SO9 Std 3A SC 3 
Sl O Std 3B AE 1 
TMalvem 
TO l Class lM SC 3 
TO2 Class 1 P AE 2 
TO3 Class 1 S AE l 
TO4 Class 2P SC 4 
TO5 Class 2M AE 2 
TO6 Std lM SC 3 
TO7 Std lP AE 1 
TO8 Std 1 S SC 4 
TO9 Std 2M SC 4 
TI O Std 2S SC 3 
Tl l Std2P AE I 
Tl 2 Std 2T AE 2 
Tl 3 Std 3M AE 1 
Tl 4 Std 3P SC 3 
TIS Std 3S AE 2 
U Savannah Park 
UOI Class IA AE 2 
UO2 Class I B AE 1 
UO3 Class 2A SC 4 
UO4 Std IA SC 3 
UO5 Std 1B AE 2 
UO6 Std 2A SC 3 
UO7 Std 2B AE I 
UO8 Std 3A SC 4 
UO9 Std 3B SC 4 
UOl O Std 3 C AE 2 
1 61 
Z Tre nance: pilot school 
ZOl Class IA Z0101 : SC EZ / Z0102 AE EZ 
Z02 Class 1 B Z0201 AE EZ 
Z03 Class 1 C Z0301 AE EZ 
Z04 Class 2A 
Z05 Class 2B Z050 I, 502 : AE EZ 
Z06 Std lA Z0601 :SC EZ / Z0602, 603, 604 :AE EZ 
207 Std 1B Z 0701,702: SC E2 / 20703: AE EZ 
208 Std IC 20801, 802: SC E2 
209 Std 2A Z0901 : AE E2 
210 Std 2B 21002 SC E2 / 21001 AE E2 
211 Std 2C 21102 SC E2 
Zl2 Std 3A Zl202 SC E2/ 21201 AE EZ 
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Appendix 2 
Sequences used for block randomisation 
1 : aerosol SW vaccine 
2 : aerosol EZ vaccine 
3 : subcutaneous SW vaccine 
4 : subcutaneous EZ vaccine 
1 l 2 3 4
2 1 24 3 
3 l 3 2 4
4 I 3 4 2 
5 142 3 
6 14 3 2 
7 2134 
8 2 143 
9 2 3 14 
10 2 3 4 I 
11 2413 
12 2 4 3 I 
13 3 1 2 4 
14 3 1 4 2 
15 3 2 14 
16 3 2 4 l 
17 3421 
18 3 4 1 2 
19 4 I 2 3 
20 4 1 3 2 
21 4213 
22 4 2 3 1 
23 4 3 I 2 
24 4 3 2 1 
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3. additional studies of safety and immunogenicity in immunologically naive younger
children;
4. use of aerosolised MMR as a booster dose to school age children (Phase I and II);
5. further evaluation of methods to deliver the nebulised vaccine to pre-school children;
6. cellular immunity after aerosol vaccination (already planned);
7. mucosa! immunity after aerosol vaccination of pre-school children;
8. potential suitability of different vaccine strains; and
9. cost/benefit of aerosol vaccination.
Co-ordination of studies in the area of alternative routes of vaccination 
WHO should convene a meeting that includes regulatory agencies and companies and 
researchers developing the three proposed products/vaccines. This meeting should focus 
upon clarifying the steps, time frames, and hurdles for bringing these products to the 
marketplace. At the end of this meeting, WHO and other collaborators should be able to 
prioritise the different approaches. Before the regulatory meeting, the developers should 
provide to WHO the projected time frame and costs of developing (and approximate unit 
costs for use) the three approaches: jet injector system, nebulised formulation, and the 
powder formulation. 
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